HTG Molecular Diagnostics (HTGMQ) 10-Q 7 Aug 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 03, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Trading Symbol	HTGM
Entity Registrant Name	HTG Molecular Diagnostics, Inc
Entity Central Index Key	1,169,987
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		6,827,414

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 11,171,021	$ 3,613,392
Short-term investments available-for-sale, at fair value	18,456,590
Accounts receivable, net	554,181	801,125
Inventory, net allowance of $265,150 at June 30, 2015 and $54,269 at December 31, 2014	2,412,093	1,685,814
Prepaid insurance	531,735	20,905
Prepaid expenses and other	236,000	91,130
Total current assets	33,361,620	6,212,366
Long-term investments available-for-sale, at fair value	14,412,979
Deferred financing and offering costs	64,105	1,369,281
Property and equipment:
Office equipment	434,729	414,424
Leasehold improvements	242,436	234,602
Laboratory and manufacturing equipment	2,682,093	2,009,818
Field equipment	164,755	286,044
Software	140,248	140,248
Property and equipment, gross	3,664,261	3,085,136
Less accumulated depreciation and amortization	(2,190,778)	(1,938,537)
Property and equipment, net	1,473,483	1,146,599
Total assets	49,312,187	8,728,246
Current liabilities:
Accounts payable	1,192,786	948,429
Accrued liabilities	1,036,974	1,499,750
Deferred revenue	28,753	41,248
NuvoGen obligation	181,250
Term loan	998,175	813,715
Total current liabilities	3,437,938	3,303,142
Redeemable convertible preferred stock warrant liability		730,543
Term loan payable - non-current, net of discount	9,669,319	9,705,655
NuvoGen obligation - non-current, net of discount	8,674,360	8,677,859
Other	43,757	58,380
Total liabilities	$ 21,825,374	22,475,579
Redeemable convertible preferred stock:
Total Redeemable Convertible Preferred Stock		$ 55,922,593
Commitments and Contingencies
Stockholders’ equity (deficit):
Preferred stock, $0.001 par value; 10,000,000 and 0 authorized at June 30, 2015 and December 31, 2014, respectively; no shares issued and outstanding at either date.
Common stock, $0.001 par value; 200,000,000 and 600,000,000 shares authorized at June 30, 2015 and December 31, 2014, respectively; 6,828,810 and 6,827,414 shares issued and outstanding, respectively, at June 30, 2015, 334,003 and 332,607 shares issued and outstanding, respectively, at December 31, 2014	$ 6,827	$ 333
Additional paid-in-capital (distributions in excess of capital)	106,264,166	(1,426,556)
Treasury stock – 1,396 shares, at cost	(75,000)	(75,000)
Accumulated deficit	(78,709,180)	(68,168,703)
Total stockholders' equity (deficit)	27,486,813	(69,669,926)
Total liabilities and stockholders' equity (deficit)	$ 49,312,187	8,728,246
Series A Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock:
Total Redeemable Convertible Preferred Stock		1,402,687
Stockholders’ equity (deficit):
Total stockholders' equity (deficit)		1,402,687
Series B Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock:
Total Redeemable Convertible Preferred Stock		2,099,310
Stockholders’ equity (deficit):
Total stockholders' equity (deficit)		2,099,310
Series C-1 Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock:
Total Redeemable Convertible Preferred Stock		4,567,525
Stockholders’ equity (deficit):
Total stockholders' equity (deficit)		4,567,525
Series C-2 Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock:
Total Redeemable Convertible Preferred Stock		2,223,506
Stockholders’ equity (deficit):
Total stockholders' equity (deficit)		2,223,506
Series D Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock:
Total Redeemable Convertible Preferred Stock		37,174,666
Stockholders’ equity (deficit):
Total stockholders' equity (deficit)		37,174,666
Series E Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock:
Total Redeemable Convertible Preferred Stock		8,454,899
Stockholders’ equity (deficit):
Total stockholders' equity (deficit)		$ 8,454,899

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Inventory net allowance	$ 265,150	$ 54,269
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	0
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	600,000,000
Common stock, shares issued	6,827,414	334,003
Common stock, shares outstanding	6,827,414	332,607
Treasury stock, shares	1,396	1,396
Series A Redeemable Convertible Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, liquidation value	$ 0	$ 1,406,369
Preferred stock, shares authorized	0	1,292,084
Preferred stock, shares issued	0	1,292,084
Preferred stock, shares outstanding	0	1,292,084
Preferred stock, par value	$ 0.001
Series B Redeemable Convertible Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, liquidation value	$ 0	$ 2,104,811
Preferred stock, shares authorized	0	11,919,624
Preferred stock, shares issued	0	6,789,712
Preferred stock, shares outstanding	0	6,789,712
Preferred stock, par value	$ 0.001
Series C-1 Redeemable Convertible Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, liquidation value	$ 0	$ 4,581,944
Preferred stock, shares authorized	0	17,530,800
Preferred stock, shares issued	0	13,342,612
Preferred stock, shares outstanding	0	13,342,612
Series C-2 Redeemable Convertible Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, liquidation value	$ 0	$ 2,244,343
Preferred stock, shares authorized	0	19,262,522
Preferred stock, shares issued	0	9,948,331
Preferred stock, shares outstanding	0	9,948,331
Series D Redeemable Convertible Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, liquidation value	$ 0	$ 68,001,923
Preferred stock, shares authorized	0	237,031,908
Preferred stock, shares issued	0	139,529,173
Preferred stock, shares outstanding	0	139,529,173
Preferred stock, par value	$ 0.001
Preferred stock, shares issued	723,050
Series E Redeemable Convertible Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, liquidation value	$ 0	$ 20,839,001
Preferred stock, shares authorized	0	185,046,445
Preferred stock, shares issued	0	45,938,041
Preferred stock, shares outstanding	0	45,938,041
Preferred stock, par value	$ 0.001

Condensed Statements of Operati

Condensed Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenue:
Product	$ 648,347	$ 75,139	$ 1,375,785	$ 445,146
Service	51,000	74,807	113,292	289,657
Other	91,204	184,429	325,789	426,095
Total revenue	790,551	334,375	1,814,866	1,160,898
Cost of revenue	834,949	615,523	1,729,575	1,257,934
Gross margin	(44,398)	(281,148)	85,291	(97,036)
Operating expenses:
Selling, general and administrative	3,726,490	2,429,388	7,165,759	4,506,190
Research and development	953,222	865,540	1,641,437	1,723,023
Total operating expenses	4,679,712	3,294,928	8,807,196	6,229,213
Operating loss	(4,724,110)	(3,576,076)	(8,721,905)	(6,326,249)
Other income (expense):
Loss from change in stock warrant valuation	(628,643)	(56,322)	(239,683)	(56,322)
Interest expense	(476,071)	(56,436)	(955,448)	(130,949)
Interest income	11,065		11,142
Loss on settlement of convertible debt	(705,217)		(705,217)
Other	70,634	4,008	70,634	1,104
Net loss before income taxes	(6,452,342)	(3,684,826)	(10,540,477)	(6,512,416)
Net loss	(6,452,342)	(3,684,826)	(10,540,477)	(6,512,416)
Accretion of stock issuance costs	(10,969)	(186,206)	(35,046)	(208,687)
Accretion of Series D and E redeemable convertible preferred stock dividends	(367,350)	(828,125)	(1,165,932)	(1,568,762)
Net loss attributable to common stockholders	$ (6,870,807)	$ (4,784,874)	$ (11,869,071)	$ (8,426,959)
Net loss per share attributable to common stockholders, basic and diluted	$ (1.73)	$ (49.62)	$ (5.49)	$ (87.39)
Shares used in computing net loss per share attributable to common stockholders, basic and diluted	3,973,055	96,440	2,163,295	96,426
Series E Warrants
Other income (expense):
Accretion of Series E warrant discount	$ (40,146)	$ (85,717)	$ (127,616)	$ (137,094)

Condensed Statements of Redeema

Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders Deficit - 6 months ended Jun. 30, 2015 - USD ($)	Total	Common Stock	Additional Paid-In-Capital (Distributions in Excess of Capital)	Treasury Stock	Accumulated Deficit	Series A Redeemable Convertible Preferred Stock	Series B Redeemable Convertible Preferred Stock	Series C-1 Redeemable Convertible Preferred Stock	Series C-2 Redeemable Convertible Preferred Stock	Series D Redeemable Convertible Preferred Stock	Series E Redeemable Convertible Preferred Stock
Balance at Dec. 31, 2014	$ (69,669,926)	$ 333	$ (1,426,556)	$ (75,000)	$ (68,168,703)	$ 1,402,687	$ 2,099,310	$ 4,567,525	$ 2,223,506	$ 37,174,666	$ 8,454,899
Balance, Redeemable convertible preferred stock shares at Dec. 31, 2014						1,292,084	6,789,712	13,242,612	9,948,331	139,529,173	45,938,041
Exercise of Series D and Series E warrants										$ 93,550	$ 11,312
Exercise of Series D and Series E warrants, shares										723,505	51,681
Exercise of stock options	$ 5,578	$ 1	5,577
Exercise of stock options, shares	1,316	1,316
Share-based compensation expense	$ 146,548		146,548
Accretion of redeemable convertible preferred stock issuance costs	(35,046)		(35,046)			$ 320	$ 839	$ 1,538	$ 2,113	$ 18,109	$ 12,127
Accretion of Series E warrant discount	(127,616)		(127,616)								127,616
Accretion of Series D and E redeemable convertible preferred stock dividend	(1,165,932)		(1,165,932)							876,955	288,977
Settlement of outstanding principal and accrued interest on convertible notes by issuance of common stock	4,544,384	$ 324	4,544,060
Settlement of outstanding principal and accrued interest on convertible notes by issuance of common stock, shares		324,591
Conversion of warrants from warrants for preferred stock to warrants for common stock	1,616,140		1,616,140
Conversion of preferred stock into common stock at initial public offering	57,356,049	$ 2,509	57,353,540			$ (1,403,007)	$ (2,100,149)	$ (4,569,063)	$ (2,225,619)	$ (38,163,280)	$ (8,894,931)
Conversion of preferred stock into common stock at initial public offering, shares		2,508,824				(1,292,084)	(6,789,712)	(13,242,612)	(9,948,331)	(140,252,678)	(45,989,722)
Issuance of common stock from initial public offering	45,357,111	$ 3,660	45,353,451
Issuance of common stock from initial public offering, shares		3,660,076
Net loss	(10,540,477)				(10,540,477)
Balance at Jun. 30, 2015	$ 27,486,813	$ 6,827	$ 106,264,166	$ (75,000)	$ (78,709,180)
Balance, shares at Dec. 31, 2014		332,607
Balance, shares at Jun. 30, 2015		6,827,414

Condensed Statements of Redeem6

Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders Deficit (Parenthetical) $ in Millions	6 Months Ended
	Jun. 30, 2015USD ($)
Statement Of Stockholders Equity [Abstract]
Initial public offering, issuance cost	$ 5.9

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Operating activities
Net loss	$ (10,540,477)	$ (6,512,416)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	299,409	240,698
Accretion of discount on NuvoGen obligation	177,751	94,684
Bad debt expense (recovery), net	33,854	102,467
Provision for excess inventory	210,881
Amortization of deferred financing costs	32,938	0
Amortization of discount on term loan	89,032
Amortization of final payment premium on term loan	59,091
Loss on settlement of convertible notes	705,217
Amortization of discount on convertible notes	90,222
Share-based compensation	146,548	81,162
Change in redeemable convertible preferred stock warrant liability	239,683	56,322
Loss on disposal of assets	70,626	35,960
Changes in operating assets and liabilities:
Accounts receivable	213,090	199,646
Inventory	(937,160)	(190,090)
Prepaid expenses and other	(657,054)	(47,284)
Accounts payable	7	(336,799)
Accrued liabilities	(418,392)	(300,316)
Deferred revenue	(12,495)	(64,548)
Net cash used in operating activities	(10,197,229)	(6,640,514)
Investing activities
Purchase of property and equipment	(444,329)	(372,640)
Purchases of available-for-sale securities	(32,877,808)
Net cash used in investing activities	(33,322,137)	(372,640)
Financing activities
Proceeds from exercise of stock options	5,578	327
Draws on line of credit		750,000
Payments on NuvoGen obligation	0	(225,000)
Proceeds from exercise of E warrants	8,948
Deferred offering costs	(1,002,930)
Deferred financing costs	(75,523)
Payments on equipment lease	(14,622)
Proceeds from issuance of convertible note warrants	1,354
Proceeds from convertible notes	4,500,000
Proceeds from initial public offering	47,654,190
Net cash provided by financing activities	51,076,995	7,910,250
Increase in cash and cash equivalents	7,557,629	897,096
Cash and cash equivalents at beginning of year	3,613,392	1,815,289
Cash and cash equivalents at end of period	11,171,021	2,712,385
Noncash investing and financing activities
Accretion of preferred stock issuance costs	35,046	208,687
Accretion of Series D and E redeemable convertible preferred stock dividends	1,165,932	1,568,762
Deferred offering costs reclassified to distributions in excess of capital	2,297,079
Allocation of Series E warrant convertible notes debt discount	741,828
Conversion of convertible notes and related accrued interest to common stock	4,544,384
Fixed asset purchases payable at period end	244,350
Reclassification of convertible preferred stock liability warrants to equity warrants	1,616,140
Supplemental cash flow information
Cash paid for interest	467,500	26,135
Common Stock
Noncash investing and financing activities
Conversion of convertible preferred stock to common stock	57,356,049
Series D and Series E Warrants
Noncash investing and financing activities
Net exercise of Series D and Series E warrants	95,914
Series E Warrants
Noncash investing and financing activities
Accretion of Series E warrant discount	127,616	137,094
Series E Redeemable Convertible Preferred Stock
Financing activities
Proceeds from sale of preferred stock, net of issuance costs		$ 7,384,923
Noncash investing and financing activities
Net exercise of Series D and Series E warrants	$ 11,312

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Description of Business	Note 1. Description of Business HTG Molecular Diagnostics, Inc. (the “Company”) is a commercial stage company that developed and markets a novel technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge platform, consisting of instrumentation (including HTG Edge and HTG EdgeSeq systems), consumables and software analytics, is used in sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. The Company’s HTG Edge platform automates the molecular profiling of genes and gene activity using its proprietary nuclease protection chemistry on a wide variety of biological samples. The Company derives revenue from the sale of instruments, consumables and related services. The Company operates in one segment and its customers are primarily located in the United States. For the three and six months ended June 30, 2015, approximately 2% and 3%, respectively, of the Company’s revenue was generated from sales to customers located outside of the United States, compared to 13% and 27%, respectively, for the three and six months ended June 30, 2014.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Note 2. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The accompanying interim unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect the accounts of the Company as of June 30, 2015. Accordingly they do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America (“GAAP”) for complete financial statements. The accompanying interim unaudited, condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and the results of its operations and cash flows, as of and for the periods presented. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. These financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the fiscal year ended December 31, 2014, included in the Company’s final prospectus supplement filed with the SEC on May 6, 2015, and related to the Company’s Registration Statement on Form S-1/A (File No. 333-201313). Reverse Stock Split On April 27, 2015, the Company effected a one-for-107.39 reverse stock split of its common stock. All common share and per common share information has been retroactively adjusted to reflect this reverse stock split. The reverse stock split did not change the number of preferred shares outstanding, only the conversion ratios associated with the preferred shares. Initial On May 11, 2015, the Company successfully completed its initial public offering (“IPO”), in which the Company sold 3,570,000 shares of common stock at $14.00 per share for total gross proceeds of approximately $50 million. An additional 90,076 shares of common stock were subsequently sold pursuant to the partial exercise by the underwriters of their over-allotment option resulting in additional gross proceeds of approximately $1.3 million. After underwriters’ fees and commissions and other expenses of the offering, the Company’s aggregate net proceeds were approximately $45.4 million. All outstanding shares of the Company’s redeemable convertible preferred stock converted into shares of common stock in connection with the IPO. Following the IPO, there were no shares of preferred stock outstanding. Liquidity The Company expects that the net proceeds from the IPO and its pre-existing cash and cash equivalents, together with interest thereon, will be sufficient to fund its operations for at least the next 12 months. However, the Company has had recurring operating losses and negative cash flows from operations since its inception. As such, the Company expects to need to raise additional equity or debt capital at some point in the future until its revenue reaches a level sufficient to provide for self-sustaining cash flows. There can be no assurance that additional equity or debt financing will be available on acceptable terms, if at all, or that the Company’s revenue will reach a level sufficient to provide for self-sustaining cash flows. The results of operations for the six months ended June 30, 2015 are not necessarily indicative of the results to be expected for the full fiscal year or any other period. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates include revenue recognition, stock-based compensation expense, the value of the warrant liability, the resolution of uncertain tax positions, income tax valuation allowances, recovery of long-lived assets and provisions for doubtful accounts, inventory obsolescence and inventory valuation. Actual results could materially differ from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash and cash equivalents. Cash and cash equivalents consist of cash on deposit with financial institutions, money market instruments and high credit quality corporate debt securities purchased with a term of three months or less. Investments The Company classifies its securities as available-for-sale, which are reported at estimated fair value with unrealized gains and losses included in accumulated other comprehensive income, net of tax. Realized gains, realized losses and declines in value of securities judged to be other-than-temporary, are included in other income (expense). The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Interest and dividends earned on all securities are included in other income (expense). Investments in securities with maturities of less than one year, or where management’s intent is to use the investments to fund current operations, or to make them available for current operations, are classified as short-term investments. If the estimated fair value of a security is below its carrying value, the Company evaluates whether it is more likely than not that it will sell the security before its anticipated recovery in market value and whether evidence indicating that the cost of the investment is recoverable within a reasonable period of time outweighs evidence to the contrary. The Company also evaluates whether or not it intends to sell the investment. If the impairment is considered to be other-than-temporary, the security is written down to its estimated fair value. In addition, the Company considers whether credit losses exist for any securities. A credit loss exists if the present value of cash flows expected to be collected is less than the amortized cost basis of the security. Other-than-temporary declines in estimated fair value and credit losses are charged against other income (expense). For the period-ended June 30, 2015, the amortized cost of investments held-for-sale approximated its fair value. Accounts Receivable, net Accounts receivable represent valid claims against debtors and have been reported net of an allowance for doubtful accounts of $118,922 and $85,068 at June 30, 2015 and December 31, 2014, respectively. Management reviews accounts receivable to identify where collectability may not be probable based on the specific identification method. Bad debt expense, net of recoveries, was $50,000 and $33,854 for the three and six months ended June 30, 2015, respectively, and $102,467 and $102,467 for the three and six months ended June 30, 2014, respectively. Fair Value of Financial Instruments The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature. Investments that are classified as available-for-sale are recorded at fair value. The fair value for securities held is determined using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. The carrying amount of the Company’s asset-secured growth capital term loan (the “Growth Term Loan”) and convertible notes were estimated using Level 3 inputs and approximates fair value since the interest rate approximates the market rate for debt securities with similar terms and risk characteristics. Inventory, net Inventory, consisting of raw materials and finished goods, is stated at the lower of cost (first-in, first-out) or market. The Company reserves or writes down its inventory for estimated obsolescence, inventory in excess of reasonably expected near term sales or unmarketable inventory, in an amount equal to the difference between the cost of inventory and the estimated market value, based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by the Company, additional inventory write-downs may be required. Inventory impairment charges establish a new cost basis for inventory and charges are not reversed subsequently to income, even if circumstances later suggest that increased carrying amounts are recoverable. For the three and six months ended June 30, 2015, the Company recorded an increase in the inventory reserve of $188,956 and $210,880, respectively, to adjust for estimated shrinkage and excess inventory. For the three and six months ended June 30, 2014, the Company recorded a decrease in the inventory reserve of $536,119 and $536,119, respectively. These amounts were recorded within cost of revenue for each year. During the quarter ended March 31, 2015, the Company determined that the average period of time customers use to evaluate the Company’s equipment generally ranges from 90 to 180 days, and in certain circumstances the evaluation period may need to be extended beyond that period. HTG Edge or HTG EdgeSeq instruments at customer locations under evaluation agreements are included in finished goods inventory. Equipment that is under evaluation for purchase remains in inventory as the Company maintains title to the equipment throughout the evaluation period. If the customer has not completed the purchase of the instrument by the end of the initial evaluation period, the Company will determine whether to extend the evaluation period or have the equipment returned to the Company. However, in no case will the evaluation period exceed one year. If the customer has not purchased the equipment or entered into a reagent agreement with the Company after evaluating for one year, the cost of the equipment is written off to cost of goods sold if the customer is allowed to continue use of the equipment. Prior to January 1, 2015, the Company recorded equipment under evaluation more than 90 days in property and equipment. The Company accordingly has reclassified from property and equipment to inventory field equipment with a net book value of $210,606 at December 31, 2014 under evaluation at that time for longer than 90 days and less than one year. Property and Equipment, net Property and equipment are stated at historical cost and depreciated over their useful lives, which range from three to five years, using the straight-line method. Leasehold improvements are amortized using the straight-line method over the lesser of the remaining lease term or the estimated useful life. Field equipment is amortized using the straight-line method over the lesser of the period of the related reagent agreement or the estimated useful life. Depreciation and leasehold improvement amortization expense was $147,916 and $299,409 for the three and six months ended June 30, 2015, respectively, and $117,285 and $225,115 for the three and six months ended June 30, 2014, respectively. Costs incurred in the development and installation of software for internal use are expensed or capitalized, depending on whether they are incurred in the preliminary project stage (expensed), application development stage (capitalized), or post-implementation stage (expensed). Amounts capitalized following project completion are amortized on a straight-line basis over the useful life of the developed asset, which is generally three years. There was no amortization expense for capitalized software costs for the three and six months ended June 30, 2015. Amortization expense for capitalized software costs was $3,896 and $15,583 for the three and six months ended June 30, 2014, respectively. Stock Issuance Costs Certain costs incurred in connection with the issuance of the Company’s Redeemable Convertible Preferred Stock (the “Preferred Stock”) have been deferred and are being accreted. Stock issuance costs have historically been accreted to distributions in excess of capital using the effective interest method. Accretion was $10,969 and $35,046 for the three and six months ended June 30, 2015, respectively, and $186,206 and $208,687 for the three and six months ended June 30, 2014, respectively. Upon automatic conversion of the Preferred Stock to common stock in connection with the closing of the Company’s IPO in May 2015, issuance costs were no longer accreted. Deferred Financing Costs and Debt Discounts Certain costs incurred in connection with the Growth Term Loan have been deferred and are being amortized. Debt issuance costs and debt discount are amortized over the term of the Growth Term Loan using the effective interest method. In addition, prior to the IPO, costs incurred in connection with the issuance of notes under the Company’s two note and warrant purchase agreements dated December 30, 2014 (the “Note Agreements”) in February and March 2015 were capitalized and amortized over the term of the Note Agreements using the straight-line accretion method, which approximated the effective interest method in this instance. The Company has recorded approximately $64,105 and $75,131 of deferred financing costs in the accompanying balance sheets as of June 30, 2015 and December 31, 2014, respectively. Deferred financing cost amortization expense for the three and six month periods ended June 30, 2015 was $14,322 and $32,938, respectively. Deferred financing cost amortization was $0 for the three and six months ended June 30, 2014. Amortization of growth term loan discount was $52,512 and $89,032 for the three and six months ended June 30, 2015, respectively, and is included in interest expense in the accompanying condensed statements of operations. Amortization of the Note Agreement discount was $63,490 and $90,222 for the three and six months ended June 30, 2015, respectively, and is included in interest expense in the accompanying condensed statements of operations. The Company compared the value of the common stock issued to settle the debt with the carrying amount of the debt at the IPO closing date of May 2015, net of unamortized discount. The Company recorded a loss on settlement of convertible debt of $705,217, comprised of $651,606 to write off unamortized discount and $53,611 to write off unamortized deferred financing costs relating to the convertible notes which were settled with common stock at the IPO, in the accompanying condensed statements of operations for the three and six months ended June 30, 2015, respectively. There was no growth term loan or convertible note discount accretion for the three and six months ended June 30, 2014. Deferred Offering Costs Deferred offering costs represent legal, accounting and other direct costs related to the IPO, which was completed in May 2015. In accounting for the IPO in May 2015, direct offering costs of approximately $2.3 million were reclassified to additional paid-in capital and are shown, along with underwriters’ fees paid, net against IPO proceeds received. The Company recorded $0 and $1.3 million of deferred offering costs as a non-current asset in the accompanying balance sheet as of June 30, 2015 and December 31, 2014, respectively. Deferred Revenue Deferred revenue represents cash receipts for products or services to be provided in future periods. When products are delivered or services are rendered, deferred revenue is then recognized as earned. Revenue Recognition The Company recognizes revenue from the sale of instruments, consumables and related services when the following four basic criteria are met: (1) a contract has been entered into with a customer or persuasive evidence of an arrangement exists, (2) delivery has occurred or services rendered, (3) the fee is fixed and determinable, and (4) collectability is reasonably assured. Sale of instruments and consumables Instrument product revenue is generally recognized upon installation and calibration by our field service engineers, unless the customer has specified any other acceptance criteria. The sale of instruments and related installation and calibration are considered to be one unit of accounting, as instruments are required to be professionally installed and calibrated before use. Installation generally occurs within a week of shipment. Consumables are considered to be separate units of accounting as they are sold separately. Consumables revenue is recognized upon transfer of ownership, which is generally upon shipment. The Company’s standard term and conditions provide that no right of return exists for instruments or consumables. Shipping and handling fees charged to the Company’s customers for instruments and consumables shipped are included in the Statements of Operations as part of product revenue. Shipping and handling costs for sold products shipped to the Company’s customers are included on the Statements of Operations as part of cost of revenue. When a contract involves multiple elements, the items included in the arrangement (deliverables) are evaluated to determine whether they represent separate units of accounting. The Company performs this evaluation at the inception of an arrangement and as each item is delivered in the arrangement. Generally, the Company accounts for a deliverable (or a group of deliverables) separately if the delivered item has stand-alone value to the customer, the customer is given a general right of return relative to the delivered item, and delivery or performance of the undelivered item or service is probable and substantially in the Company’s control. When multiple elements can be separated into separate units of accounting, arrangement consideration is allocated at the inception of the arrangement, based on each deliverables’ relative selling price. All revenue from contracts determined not to have separate units of accounting is recognized based on consideration of the most substantive delivery factor of all the elements in the contract. The Company provides instruments to certain customers under a reagent agreement. Under these agreements, the Company installs instruments in the customer’s facility without a fee and the customer agrees to purchase consumable products at a stated price over the term of the agreement; in some instances the agreements do not contain a minimum purchase requirement. Terms range from several months to multiple years and may automatically renew in several month or multiple year increments unless either party notifies the other in advance that the agreement will not renew. This represents a multiple element arrangement and because all consideration under the reagent agreement is contingent on the sale of consumables, no consideration has been allocated to the instrument and no revenue has been recognized upon installation of the instrument. The Company expects to recover the cost of the instrument under the agreement through the fees charged for consumables, to the extent sold, over the term of the agreement. Revenue is recognized as consumables are shipped. In reagent rental agreements, the Company retains title to the instrument and title is transferred to the customer at no additional charge at the conclusion of the initial arrangement. Because the pattern of revenue from the arrangement cannot be reasonably estimated, the cost of the instrument is amortized on a straight-line basis over the term of the arrangement, unless there is no minimum consumable product purchase in which case the instrument would be expensed as cost of goods sold. Cost to maintain the instrument while title remains with the Company is charged to cost of sales as incurred. Service Revenue For contracts related to custom panel design services and sample processing, the Company utilizes a proportional performance revenue recognition model, under which revenue is recognized as performance occurs based on the relative outputs of the performance that have occurred up to that point in time under the respective agreement. The Company includes all applicable costs incurred related to custom panel design services, including research and development costs and general and administrative expenses, in cost of revenue. The Company also provides contract research services under cost plus fixed fee government contracts. Revenue is recognized under government contracts using the percentage-of-completion method of accounting. Under the percentage-of-completion method, contract research revenue is recognized as the work progresses and services are rendered and costs are incurred. The fixed fee is recognized in proportion to costs incurred compared to total estimated costs. The Company includes all applicable costs incurred from government contracts, including general and administrative expenses on government contracts, in cost of revenue. Anticipated losses, if any, on contracts are charged to earnings as soon as they are identified. Anticipated losses cover all costs allocable to contracts. Revenue arising from claims or change orders is recorded either as income or as an offset against a potential loss only when the amount of the claim can be estimated and its realization is probable. Other Revenue Other revenue includes license and grant revenue. License revenue is generated from the licensing of the Company’s internally developed intellectual property to third parties. The revenue may be generated by nonrefundable up-front payments and license fees, milestone and other contingent payments, or royalties based on sales of commercialized products. Licensing fees are recognized on a straight-line basis over the term of the license agreement for agreements requiring specific continuing performance obligations with deferral of all or a portion of these fees. If it cannot be concluded that a license fee is fixed or determinable at the outset of an arrangement, amounts are recognized as income as payments from third parties become due. No licensing fees were included in other revenue for the three and six months ended June 30, 2015 and 2014. Grant revenue is earned when expenditures relating to the projects under these awards are incurred. Concentration Risks Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and uncollateralized accounts receivable. The Company maintains the majority of its cash balances in the form of cash deposits in bank checking and money market accounts in amounts in excess of federally insured limits. Management believes, based upon the quality of the financial institution, that the credit risk with regard to these deposits is not significant. The Company sells its instruments, consumables, sample processing services, custom panel design services and contract research services primarily to biopharmaceutical companies, academic institutions and molecular labs. The Company routinely assesses the financial strength of its customers and credit losses have been minimal to date. The top three customers accounted for 44%, 7% and 6% of the Company’s revenue for the three months ended June 30, 2015, compared with 12%, 6% and 6% for the three months ended June 30, 2014. The largest two customers accounted for 31% and 15% of the Company’s revenue for the six months ended June 30, 2015. The largest three customers accounted for 15%, 9% and 7% for the six months ended June 30, 2014. The Company derived 12% and 18% of its total revenue from grants and contracts, primarily from one organization during the three and six month periods ended June 30, 2015, respectively. 56% and 37% of total revenue was derived from grants and contracts primarily from one organization, during the three and six month periods ended June 30, 2014, respectively. The largest two customers accounted for approximately 57% and 9% of the Company’s net accounts receivable as of June 30, 2015. One customer accounted for approximately 31% of the Company’s net accounts receivable at December 31, 2014. The Company currently relies on a single vendor to manufacture its HTG Edge processor and reader and HTG EdgeSeq processor and additional single suppliers to supply subcomponents used in the processor. A loss of any of these suppliers could significantly delay the delivery of HTG Edge systems, which in turn would materially affect the Company’s ability to generate revenue. New Accounting Pronouncements In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing GAAP. The revised revenue standard is effective for public entities for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is currently evaluating the impact of our pending adoption of ASU 2014-09 on our financial statements and has not yet determined the method by which we will adopt the standard. In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Going Concern (“ASU 2014-15”). ASU 2014-15 provides GAAP guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The standard will be effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016. Early application is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. The Company does not believe the adoption of this standard will have a significant impact on the Company’s financial statements. In April 2015, the FASB issued an accounting standards update entitled “ASU 2015-03, Interest – Imputation of Interest: Simplifying the presentation of Debt Issuance Costs”. The standard requires entities to present debt issuance costs on the balance sheet as a direct deduction from the related debt liability rather than as an asset, and the amortization is reported as interest expense. The result of application of this guidance would be to reduce the deferred financing costs balance, with a corresponding reduction to the long term liabilities to which the debt issuance costs relate in the condensed balance sheets. The standard does not affect recognition and measurement of debt issuance costs. The Company expects to adopt ASU 2015-03 on January 1, 2016. In July 2015, the FASB issued an accounting standards update entitled “ASU 2015-11, Inventory: Simplifying the Measurement of Inventory”. The standard requires inventory within the scope of the ASU to be measured using the lower of cost and net realizable value. The changes apply to all types of inventory, except those measured using LIFO or retail inventory method, and are intended to more clearly articulate the requirements for the measurement and disclosure of inventory and to simplify the accounting for inventory by eliminating the notions of replacement cost and net realizable value less a normal profit margin. The standard will be effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016. The Company does not believe the adoption of this standard will have a significant impact on the Company’s financial statements.

Inventory

Inventory	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Inventory	Note 3. Inventory Inventory, net of reserves, consisted of the following as of the date indicated: June 30, December 31, 2015 2014 Raw materials $ 228,954 $ 174,150 Work in process — — Finished goods 2,183,139 1,511,664 $ 2,412,093 $ 1,685,814

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 4. Fair Value Instruments Fair value measurements used by the Company for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements are based on the premise that fair value represents an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the following three-tier fair value hierarchy has been used in determining the input used in measuring fair value: Level 1 – Quoted process in active markets for identical assets or liabilities on the reporting date. Financial assets in Level 1 include the amounts held in money market accounts classified as cash equivalents. Level 2 – Pricing inputs are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Pricing inputs are generally unobservable and include situations where there is little, if any, market activity for the investment. The inputs into the determination of fair value require management’s judgment or estimation of assumptions that market participants would use in pricing the assets or liabilities. The fair values are therefore determined using factors that involve considerable judgment and interpretations, including but not limited to private and public comparables, third-party appraisals, discounted cash flow models, and fund manager estimates. Financial liabilities in this category include the Company’s preferred stock warrants. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within which the fair value measurement is categorized is based on the lowest level input that is significant to the fair value measurement. We measure the fair values of these assets and liabilities based on prices provided by independent market participant that are based on observable inputs using market-based valuation techniques. These valuation models and analytical tools use market pricing or similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. The Company did not adjust any of the valuations received from these third parties with respect to any of its level 1 securities at June 30, 2015 or December 31, 2014. Our portfolio of securities comprises U.S. Treasuries, U.S. government sponsored agency obligations and high credit quality corporate debt securities classified as available-for-sale securities. Unrealized gains and losses will be included in accumulated other comprehensive income, net of tax. Realized gains, realized losses and declines in value of securities judged to be other-than-temporary, will be included in other income (expense). For the period-ended June 30, 2015, the amortized cost of investments held-for-sale approximated its fair value. The following table provides information about the Company’s financial assets and liabilities measured at fair value on a recurring basis at June 30, 2015 and December 31, 2014, respectively: Balance at June 30, 2015 Level 1 Level 2 Level 3 Balance at December 31, 2014 Level 1 Level 2 Level 3 Asset included in: Cash and cash equivalents Money market securities $ 9,666,594 $ 9,666,594 $ — $ 3,608,890 $ 3,608,890 $ — $ — Corporate debt securities $ 1,499,462 $ — $ 1,499,462 $ — $ — $ — $ — $ — Investments at fair value U.S. government obligations $ 3,307,680 $ 3,307,680 $ — $ — $ — $ — $ — $ — U.S. government agency obligations $ 14,717,062 $ — $ 14,717,062 $ — $ — $ — $ — $ — Corporate debt securities $ 14,844,827 $ — $ 14,844,827 $ — $ — $ — $ — $ — Liabilities: Growth Term Loan warrants $ — $ — $ — $ — $ 301,508 $ — $ — $ 301,508 Preferred Stock warrants $ — $ — $ — $ — $ 429,035 $ — $ — $ 429,035 There are no other financial instruments subject to fair value measurement on a recurring basis. Initial investment in available-for-sale securities was made during the quarter ended June 30, 2015 as a result of funding received through the Company’s IPO. Level 1 instruments include investments in money market funds and U.S. Treasuries. These instruments are valued using quoted market prices for identical unrestricted instruments in active markets. The Company defines active markets for debt instruments based on both the average daily trading volume and the number of days with trading activity. Level 2 instruments include U.S. Government agency obligations and corporate debt securities. Valuations of Level 2 instruments can be verified to quoted prices, recent trading activity for identical or similar instruments, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. Consideration is given to the nature of the quotations (e.g. indicative or firm) and the relationship of recent market activity to the prices provided from alternative pricing sources. Transfers to/from Levels 1, 2, and 3 are recognized at the end of the reporting period. There were no transfers between levels for the three and six months ended June 30, 2015 or the year ended December 31, 2014. The Company used its May 2015 IPO pricing as an input for measurement of the fair value of its Level 3 preferred stock warrant liabilities at May 11, 2015 and the Black-Scholes option pricing model, and other valuation models for measuring the fair value of its Level 3 preferred stock warrant liabilities at December 31, 2014. The outstanding preferred stock warrants were converted to common stock warrants in connection with the closing of the Company’s IPO. The Company’s warrant liabilities at December 31, 2014 were categorized as Level 3 because they were valued based on unobservable inputs and management judgment due to the absence of quoted market prices, inherent lack of liquidity and the long-term nature of such financial instruments. As a result of their conversion to common stock warrants on May 11, 2015 with our IPO, there were no warrant liabilities outstanding at June 30, 2015. The December 31, 2014 fair value assessments used the Black-Sholes option pricing model using the following assumptions: December 31, 2014 Fair value of Series B/C/D Stock and Series E Stock shares on grant date or measurement date $0.14 - $0.22 Exercise price $0.01 - $0.346 Expected risk-free interest rate 1.20% Expected volatility 70% Expected term 4.1 years Expected dividend yield 0 - 8% The volatility assumption is based on the volatility of publicly traded industry competitors as adjusted for future expectations. The expected term was based on the Company’s historical experience and future expectations with regard to the exercise of the preferred stock warrants and the probability of conversion of the underlying preferred stock. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected terms of the warrants. At December 31, 2014 the fair value of the Company’s redeemable convertible preferred stock was determined by a valuation model that considered both income and market-based valuations of the Company’s enterprise value. The expected dividend yield at December 31, 2014 is consistent with the dividend rate on the Company’s redeemable convertible preferred stock. The assumptions used in the Black-Scholes option pricing model are inherently subjective and involve significant judgment. Any change in the fair value was recognized as a component of other income (expense) in the statements of operations. A reconciliation of the beginning and ending liabilities measured at fair value on a recurring basis using Level 3 inputs for June 30, 2015 and June 30, 2014 are as follows: June 30, 2015 June 30, 2014 Beginning balance $ 730,543 $ 44,120 Issuance of Series E Preferred Stock Warrants — 1,890,000 Exercise of Series E Preferred Stock Warrants (4,116 ) (1,890,000 ) Exercise of Series D Preferred Stock Warrants (91,798 ) — Reclassification of Series C-2 Warrants to Common Stock Warrants (555 ) — Reclassification of Growth Term Loan Warrants to Common Warrants (229,550 ) — Issuance of Convertible Note Warrants 741,828 — Reclassification of Convertible Note Warrants to Common Stock Warrants (1,386,035 ) — Change in preferred stock warrant valuation 239,683 56,322 Ending balance $ — $ 100,442

Debt Obligations

Debt Obligations	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Debt Obligations	Note 5. Debt Obligations. Growth Term Loan In August 2014, the Company entered into the Growth Term Loan with a syndicate of two lending institutions. The first tranche of the Growth Term Loan (“Growth Term Loan A”) of $11.0 million was funded at closing with a second tranche of $5.0 million (“Growth Term Loan B”) which was initially available to be drawn until July 4, 2015. In August 2015, the Company and its lenders amended the Growth Term Loan agreement to extend the draw period for the second tranche until March 31, 2016 (See Note 14 – Subsequent Events). The second tranche funding was not drawn prior to expiration of this 60 day period. The Company received the first tranche proceeds, net of a $0.3 million original issue discount. The Company also booked a discount for the issuance of warrants with the debt (See Note 8). The original issuance discount and warrant discount are being amortized, using the effective interest method, over the term of the Growth Term Loan A. Amortization expense was $52,512 and $89,032 for the three and six months ended June 30, 2015, respectively, and is included in interest expense in the accompanying condensed statements of operations. There was no amortization expense for the three and six months ended June 30, 2014. The Growth Term Loan A bears interest at the fixed rate of 8.5% and matures in September 2018. Pursuant to the August 2015 amendment to the Growth Term Loan agreement, the Company will have monthly interest-only payment obligations until April 1, 2016. Following the interest-only payment period, equal monthly payments of $408,296 consisting of principal and interest amortized over the remaining term of the loan were due. The condensed balance sheets and the principal repayments table below have been adjusted to reflect this amended payment schedule. The Growth Term Loan requires the Company to maintain compliance with specific reporting covenants and does not require financial covenants. The Growth Term Loan is secured by a lien covering substantially all of the Company’s assets, excluding patents, trademarks and other intellectual property rights (except for rights to payment related to the sale, licensing or disposition of such intellectual property rights) and certain other specified property. The Company paid $0.1 million in financing costs upon entering the Growth Term Loan. The agreement included preferred stock warrants to purchase 2,512,562 shares of Series E Stock (“the “Series E Loan Warrants”) at a price of $0.2189 per share or at the purchase price of the next round of equity sold if no further shares of Series E Stock were sold. The warrants to purchase shares of Series E Stock expire on August 22, 2024 (See Note 8) and were automatically converted to common stock warrants upon completion of the Company’s IPO in May 2015. The principal repayments due under the term loan as of June 30, 2015, are as follows: 2015 $ — 2016 3,059,068 2017 4,393,103 2018 3,547,829 Total Growth Term Loan payments 11,000,000 Less discount (447,799 ) Plus final fee premium 115,292 Total Growth Term Loan, net $ 10,667,493 Convertible Notes On December 30, 2014, the Company entered into two, separate subordinated convertible promissory note agreements, (“the Note Agreements”). The Note Agreements provided that upon a qualified equity financing, pursuant to which the Company raised either through a qualified initial public offering of common stock (“IPO”) or through a qualifying private placement of preferred stock, gross offering proceeds of at least $20,000,000 from the sale of shares to new investors, the outstanding principal amount and all accrued but unpaid interest under the Note Agreements would automatically convert into shares of common or preferred stock, whichever was sold in the offering. The number of shares into which the notes may be converted, common shares in the case of a qualified initial public offering or preferred shares in the case of a qualified private placement, is equal to the outstanding principal and accrued interest divided by the price per share paid by investors purchasing such newly issued equity securities. The Note Agreements also provide that in the event of a sale of the Company, the holders may elect to receive two times the outstanding principal and accrued interest or the number of shares of Series E preferred stock as is equal to the outstanding principal and accrued interest divided by $0.2189. Under the first Note Agreement, the Company was able to issue up to $7,339,165 of notes to existing investors at five future, individual closings of up to $1,500,000 each upon ten days’ notice to participating investors . Under the second Note Agreement, the Company was able to issue up to $6,203,971 of subordinated convertible notes to existing investors at four individual closings of up to $1,703,971 each upon ten days’ notice to participating investors. When issued, the notes bear annual interest at 8% and mature on March 31, 2016. In addition, pursuant to the second Note Agreement the Company issued to participating investors warrants to purchase up to 4,282,472 shares of Series E preferred stock at $0.2189 per share, discussed further in Note 8. Under each of the Note Agreements, the failure of a principal or major participating investor to invest their committed amount at each of the closings resulted in the conversion of a percentage of the investor’s preferred shares into common shares at the applicable conversion rates in effect pursuant to the Company’s restated certificate of incorporation. Under the first Note Agreement, failure of a principal investor to purchase their committed amount resulted in the conversion of their entire holdings of preferred stock into common stock, at conversion rates then in effect. Under the second Note Agreement, up to 80% of the total preferred stock held by such investor will be converted into common stock, at conversion rates then in effect. In addition, failure to purchase the full committed amount in any closing will result in the termination of the applicable investor’s warrants, in whole or in part, and the forgiveness and extinguishment of 80% of the aggregate principal amount of the applicable investor’s outstanding notes, if any. In the event the Company sold new shares of stock in a qualified initial public offering or preferred stock in a private placement, an investor’s failure to participate in the subsequent equity financing, in an amount equal to their applicable remaining committed amount under the Note Agreements, would result in the conversion of up to 80% of the non-participating investor’s aggregate preferred stock holding as of the closing date of the subsequent equity financing, along with a reduction of up to 80% of the non-participating investor’s warrants. Pursuant to the provisions of the second Note Agreement, certain preferred shares were optionally converted into common stock as of December 30, 2014. Certain provisions of the first Note Agreement terminate (including the investors’ obligations to purchase notes thereunder) immediately prior to the earlier to occur of the closing of (i) a qualified initial public offering or (ii) a qualified private placement. Certain provisions of the second Note Agreement terminate (including the investors’ obligations to purchase notes thereunder) immediately prior to the earlier to occur of (x) the time at which a registration statement covering a public offering of the Company’s securities under the Securities Act of 1933, as amended, becomes effective or (y) the initial closing of a qualified private placement. Such provisions of the Note Agreements (including the investors’ obligations to purchase notes thereunder) terminated in connection with the completion of the Company’s IPO. As of December 31, 2014, there were no borrowings under the Note Agreements. Draws under the first Note Agreement in February, March and April 2015 totaled $4.5 million through the Company’s IPO in May 2015. There were no draws under the second Note Agreement prior to the Company’s IPO in May 2015. The Company booked a $741,828 discount for the estimated fair value of warrants issued in connection with the debt (See Note 8). The warrant discount is being amortized, using the effective interest method, over the term of the Convertible Notes. Amortization expense of $63,490 and $90,222 for the three and six months ended June 30, 2015, respectively, is included in the statement of operations. There was no amortization expense for the three and six months ended June 30, 2014. Settlement of Convertible Debt upon IPO Closing Upon closing of the Company’s initial public offering in May 2015, all outstanding principal and accrued interest was settled by issuing 324,591 shares of common stock valued at the IPO price of $14.00 for a total of $4.5 million. The Company evaluated the terms of the Note Agreement at inception and concluded that it should be accounted for as share settled debt as it falls within the scope of ASC 480, “Distinguishing Liabilities from Equity”. While the issued debt Note Agreements contain multiple events that could trigger settlement at different values, the Company evaluated all of the possible outcomes and considered the qualified IPO outcome to be predominant at more than 50%. The IPO settlement triggering event settles the fixed monetary amount of the debt known at inception with a variable number of shares of common stock based on the price of the common stock at settlement and therefore meets the definition of share settled debt. The Company compared the value of the common stock issued to settle the debt with the carrying amount of the debt at the IPO closing date of May 2015, net of unamortized discount and deferred financing costs, and recorded a loss on settlement of debt of $705,217 in the accompanying condensed statement of operations for the three and six months ended June 30, 2015. The value of the debt adjusted to the value of the common stock paid was reclassified from debt to equity.

Other Agreements

Other Agreements	6 Months Ended
	Jun. 30, 2015
Other Agreements [Abstract]
Other Agreements	Note 6. Other Agreements NuvoGen Obligation The Company entered into an asset purchase agreement in 2001, as amended, with NuvoGen Research, LLC (“NuvoGen”) to acquire certain intellectual property from NuvoGen. The Company accounted for the transaction as an asset acquisition. However, as the intellectual property was determined to not have an alternative future use, the upfront consideration was expensed. The Company exchanged upfront consideration of 600,000 shares of the Company’s common stock. The remaining cash consideration of $15,000,000 is to be paid by the Company through a percentage of applicable annual sales equal to the greater of a minimum annual payment or 6% of the Company’s applicable annual revenues. The obligation is non-interest bearing and was secured by certain patents and trademarks. Certain terms of the agreement were amended in November 2012 and February 2014. The Company recorded the obligation at the estimated present value of the future payments using a discount rate of 2.5%, the Company’s estimate of its effective borrowing rate for similar obligations. Unamortized debt discount was $386,883 and $564,634 at June 30, 2015 and December 31, 2014, respectively. Pursuant to the closing of the Growth Term Loan in August 2014 (See Note 5), the Company agreed to accelerate certain minimum payments pursuant to the asset purchase agreement and NuvoGen agreed to terminate its security interest in the originally pledged patents and trademarks. Remaining minimum payments that were otherwise due for 2014, 2015 and the first quarter of 2016, amounting to $868,750 were paid in advance. No further payment is due under the asset purchase agreement until the second quarter of 2016. The acceleration of payments did not significantly change the minimum cash flows and therefore had no significant accounting effect. There were no payments made to NuvoGen during the three and six months ended June 30, 2015. NuvoGen was paid $112,500 and $225,000, respectively, during the three and six months ended June 30, 2014. Discount accreted during the three and six months ended June 30, 2015 was $51,180 and $177,751, respectively, and $47,184 and $94,684, during the three and six months ended June 30, 2014, respectively. The remaining payments due to NuvoGen at June 30, 2015, are as follows: 2015 $ — 2016 543,750 2017 800,000 2018 400,000 2019 400,000 2020 and beyond 7,098,743 $ 9,242,493 Illumina, Inc. Agreement In October 2014, the Company entered into a development and component supply agreement with Illumina, Inc. for the development and worldwide commercialization by the Company of up to two complete diagnostic gene expression profiling tests for with Illumina’s diagnostic instruments, using components supplied by Illumina. The Company refers to these diagnostic gene expression profiling tests as IVD test kits. The IVD test kits may be used in two discrete testing fields chosen by the Company, one or both of which may relate to oncology for breast, lung, lymphoma or melanoma tumors, and up to one of which may relate to transplant, chronic obstructive pulmonary disease, or immunology/autoimmunity. The Company provided notice to Illumina of its first testing selections during the quarter ended March 31, 2015. If a second selection is to be selected, the Company must provide notice to Illumina of the Company’s second selected field within 24 months following the date of the agreement. Following the Company’s selection of the testing field for each IVD test kit, the Company and Illumina have agreed to negotiate a development plan for the development and regulatory approval of the applicable IVD test kit. Illumina has agreed to provide development and regulatory support as part of the plan. Upon mutual agreement of the first development plan, the Company will pay Illumina a fixed fee in the six-figure dollar range. The Company is also required to pay Illumina up to $1.0 million in the aggregate upon achievement of specified regulatory milestones relating to the IVD test kits. In addition, the Company has agreed to pay Illumina a single digit percentage royalty on net sales of any IVD test kits that the Company commercializes pursuant to the agreement. As of June 30, 2015 the first development plan has not been completed. Ongoing research and development costs for these programs have been expensed as incurred and $0 has been paid to Illumina relating to this agreement as of June 30, 2015. The agreement will expire on the earlier of October 2019 or the date which the last to expire development plan under the agreement is completed. The Company may terminate the agreement at any time upon 90 days’ written notice and may terminate any development plan under the agreement upon 30 days’ prior written notice. Illumina may terminate the agreement upon 30 days’ prior written notice if the Company undergoes certain changes of control or immediately if the Company fails to select a testing field for an IVD test kit within 24 months following the date of the agreement. Either party may terminate the agreement upon the other party’s material breach of the agreement that remains uncured for 30 days, or upon the other party’s bankruptcy.

Net Loss per Share

Net Loss per Share	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Net Loss per Share	Note 7. Net Loss Per Share Net loss attributable to common stockholders per share is computed by dividing the net loss allocable to common stockholders by the weighted-average number of shares of common stock or common stock equivalents outstanding. Outstanding stock options, warrants and preferred stock have not been included in the calculation of diluted net loss attributable to common stockholders per share because to do so would be anti-dilutive. Accordingly, the numerator and the denominator used in computing both basic and diluted net loss per share for each period are the same. The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss per share: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Numerator: Net loss $ (6,452,342 ) $ (3,684,826 ) $ (10,540,477 ) $ (6,512,416 ) Accretion of stock issuance costs (10,969 ) (186,206 ) (35,046 ) (208,687 ) Accretion of discount on Series E warrants (40,146 ) (85,717 ) (127,616 ) (137,094 ) Series E and D, preferred stock dividends (367,350 ) (828,125 ) (1,165,932 ) (1,568,762 ) Net loss attributable to common stockholders $ (6,870,807 ) $ (4,784,874 ) $ (11,869,071 ) $ (8,426,959 ) Denominator: Weighted-average common shares outstanding -basic and diluted 3,973,055 96,440 2,163,295 96,426 The following outstanding options, warrants and preferred stock were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Six Months Ended June 30, 2015 2014 Options to purchase common stock 610,090 553,622 Convertible preferred stock (as converted) — 2,353,163 Convertible preferred stock warrants (as converted) — 27,534 Common stock warrant 170,587 931

Warrants

Warrants	6 Months Ended
	Jun. 30, 2015
Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants [Abstract]
Warrants	Note 8. Warrants In connection with certain of its redeemable convertible preferred stock issuances, convertible debt financings and other financing arrangements, the Company has issued warrants for shares of its common stock and various issues of its redeemable convertible preferred stock. On August 22, 2014, in connection with the Company’s entry into the Growth Term Loan, the Company issued to the lenders Series E Loan Warrants exercisable for an aggregate of 2,512,562 shares of Series E preferred stock at a price of $0.2189 per share. The warrants provided for cashless exercise at the option of the holders, and also contained provisions for the adjustment of the number of shares issuable upon the exercise of the warrant in the event of stock splits, recapitalizations, reclassifications, consolidations or dilutive issuances. In connection with the completion of the initial public offering in May 2015, the Series E Loan Warrants became exercisable for an aggregate of 23,396 shares of the Company’s common stock at an exercise price of $23.51 per share. The Series E Loan Warrants expire by their terms on August 22, 2024, provided that the warrants will be automatically exercised on a cashless basis upon expiration if not previously exercised if the fair market value of a share of the Company’s common stock exceeds the per share exercise price. The Company allocated the total proceeds of the Growth Term Loan and the Series E Loan Warrants based on the residual value method. Assumptions used to determine the initial fair value included fair value of shares of Series E Stock on grant date $0.31; Exercise price $0.2189; Expected risk-free interest rate 1.6%; Expected volatility 70.0%; Expected term 4.5 years; and Expected dividend yield 8.0%. The fair value of the Series E Warrants of $0.12 per share, or $301,507, was recorded as a discount on the Growth Term Loan to be accreted over the term of the Growth Term Loan using the effective interest method. The Company has historically accounted for the Series E Loan Warrants as liabilities as such warrants were indexed to shares that could be redeemed for cash outside the control of the Company. The preferred warrants were valued using the Black-Scholes option pricing model as of December 31, 2014. At December 31, 2014, the fair value of the Series E Loan Warrants was $301,507. Refer to Note 4 for assumptions used to value these warrants. On December 30, 2014, in connection with the Company’s Note and Warrant Purchase Agreements (Note 5) the Company agreed to issue warrants (the “Convertible Note Warrants”) exercisable for an aggregate of 9,311,586 shares of Series E Stock at a price of $0.2189 per share, for aggregate consideration of $1,354. The Convertible Note Warrants were issued on January 15, 2015. The warrants provide for cashless exercise at the option of the holders, and also contained provisions for the adjustment of the number of shares issuable upon the exercise of the warrant in the event of stock splits, recapitalizations, reclassifications, consolidations or dilutive issuances. The Convertible Note Warrants expire by their terms on January 15, 2022. As the Convertible Note Warrants were issued in conjunction with and in order to establish a lending facility commitment, they were being accounted for as a debt discount to be amortized over the life of the Note Agreements using the effective interest method and as a warrant liability, at fair value, as they were indexed to shares that could be redeemed for cash outside the control of the Company. The Company recorded the initial $741,828 of the Convertible Note Warrants using the Black-Scholes option pricing model and assumptions further described in Note 4, specifically using a 7 year term, a 1.6% risk free interest rate, 75% volatility, 0% dividend yield and a common stock price of $0.13 which is a pre-IPO equivalent to the Company’s $14.00 per share offering price in May 2015, which the Company considered to approximate the fair value at January 14, 2015 as the operations of the business had not changed during the intervening period. Upon closing of the IPO, the Company’s preferred stock warrants expired, were exchanged for equity warrants or were exercised by the holders, depending on the terms of the respective agreements and actions of the holders. The Company computed the fair value of the warrants just prior to the conversion date and the change in fair value was recorded to loss from change in stock warrant valuation within the statements of operations. The Company’s Series C-1 preferred stock warrants expired upon closing of the IPO as they were not exercised prior to or contemporaneously with the closing of the IPO. As of May 11, 2015, 1,290,350 Series C-1 preferred stock warrants were forfeited and cancelled as they were not exercised prior to the initial public offering. The Company resolved that, in accordance with the Conversion Agreement, dated December 22, 2014, effective immediately prior to the closing of the IPO, each share of preferred stock of the Company then outstanding and unexpired would automatically be converted into shares of the Company’s common stock. Due to the conversion of the underlying Series C-2 Stock and Series E Stock into common stock, the Series C-2, Series E and Convertible Note preferred warrants became exercisable for common stock. Following conversion to common stock warrants, these warrants were determined to meet the criteria for equity classification. Upon completion of the IPO, and the conversion of the Company’s Series C-2 preferred stock into common stock, the Series C-2 preferred stock warrants converted to warrants for purchase of 1,488 shares of the Company’s common stock at an exercise price of $24.23 per share. The Convertible Note Warrants converted to warrants for the purchase of 144,772 shares of the Company’s common stock at the initial public offering price of $14.00 per share. Series E Loan Warrants converted to warrants for the purchase of 23,396 shares of the Company’s common stock at the initial public offering price of $14.00 per share. During 2015, all series D preferred stock warrant holders elected to exercise their warrants, contingent and effective upon closing of the IPO. Upon completion of the IPO, the Company issued 723,050 shares of its Series D preferred stock upon the exercise of 769,059 outstanding warrants, for which it received aggregate cash consideration of approximately $1,752 for such exercises. Certain warrant holders elected to exercise pursuant to the terms of the net exercise provision of the warrant. For purposes of such net exercise, the fair market value of the Company’s common stock was equal to the initial public offering price of $14.00. The Series D preferred stock converted into 6,729 shares of the Company’s common stock on May 11, 2015. Security Number of Preferred and Common Warrants at December 31, 2014 Number of Common Warrants at June 30, 2015 Exercise Price/Share Expiration Date Series C-1 redeemable convertible preferred stock warrants 1,290,350 — $ 37.16 2016-2017 Series C-2 redeemable convertible preferred stock warrants 157,912 1,488 24.23 2015 Series D redeemable convertible preferred stock warrants 769,059 — 1.07 2020 Series E redeemable convertible preferred stock warrants 2,512,562 23,396 23.51 2024 Convertible note warrants — 144,772 14.00 2022 Common stock warrants 931 931 6.45 2019 The fair value of the preferred stock warrant liability was $0 and $730,543 at June 30, 2015 and December 31, 2014, respectively. During the three and six months ended June 30, 2015 the Company recorded a loss of $628,643 and $239,383, respectively, on the change in fair value of the preferred stock warrants, as the fair value of all preferred stock warrants was updated prior to conversion at IPO, with the fair value change being charged to loss from change in stock warrant valuation in the statements of operations. A loss of $56,322 and $56,322, respectively, was recorded during the three and six months ended June 30, 2014 on the change in fair value of the preferred stock warrants. The preferred stock warrant liability for outstanding Series C-2, Series D and Series E warrants was reclassified to additional paid-in-capital and recorded as common stock warrants upon the closing of the Company’s IPO.

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Redeemable Convertible Preferred Stock	Note 9. Redeemable Convertible Preferred Stock On February 4, 2014, the Company entered into the Series E Preferred Stock and Warrant Purchase Agreement (the “Series E Agreement”) authorizing the sale and issuance of up to 99,132,024 shares of its Series E Stock for $0.2189 per share and warrants (the “Series E Warrants”) to purchase up to an aggregate of 33,044,008 shares of Series E Stock at an exercise price of $0.001 per share. Pursuant to the Series E Agreement, up to 49,566,012 shares of Series E Stock together with Series E Warrants to purchase up to an aggregate of 16,522,004 shares of Series E Stock would be offered at one or more closings of a first tranche and the remainder of which will be offered in a second tranche. As a result of the Series E Preferred Agreement, the Company’s authorized shares were increased to 600,000,000 shares of Common Stock and 472,083,383 shares of Preferred Stock. On February 4, 2014 the Company issued 34,099,476 shares of Series E Stock pursuant to the Series E Agreement at a price per share of $0.2189 per share. Along with the shares of Series E Stock, one Series E Warrant was issued for every three shares of Series E Stock purchased with a purchase price of $0.0001 per Series E Warrant and an exercise price of $0.001 per share of Series E Stock for a total of 11,366,486 Series E Warrants. Each Series E Stock purchaser was required to exercise the Series E Warrant in a simultaneous transaction with the purchase of shares of Series E Stock. Together with the Series E Warrants, the issuance of shares of Series E Stock and Series E Warrants resulted in gross proceeds to the Company of $7,476,879. On March 31, 2014, pursuant to a rights offering, the Company issued 354,062 shares of Series E Stock pursuant to the Series E Agreement at a price per share of $0.2189 per share. Along with the shares of Series E Stock, one Series E Warrant was issued for each three shares of Series E Stock purchased with a purchase price of $0.0001 per Series E Warrant and an exercise price of $0.001 per share of Series E Stock for a total of 118,017 Series E Warrants. Each Series E Stock purchaser was required to exercise the Series E Warrant in a simultaneous transaction with the purchase of shares of Series E Stock. Together with Series E Warrants, the issuance of shares of Series E Stock and Series E Warrants resulted in gross proceeds to the Company of $77,634. The Series E Agreement provided for a second tranche on or before November 30, 2014, contingent upon the achievement of certain milestones. It was determined that, given the nominal strike price of the Series E Warrants and the fact that the Series E Preferred Warrants were required to be exercised immediately upon issuance, the per share value of the Series E Warrants would be similar to the effective per share value of the Series E Stock, or $0.1645 per share. The second closing under the Series E Agreement, originally scheduled to occur on or before November 31, 2014, was replaced by an alternative financing in the form of subordinated convertible promissory notes as discussed further in Note 5. The Series A/B/C/D Stock and Series E Stock have a par value of $0.001 per share. The Series D Stock and Series E Stock liquidation preference was equal to two times the original issue price of the Series D Stock or Series E Stock, respectively, plus any accrued but unpaid dividends whether or not declared. The Company has historically accreted up to the redemption amount and not the liquidation value, because additional amounts due under the liquidation rights was not considered probable at initial recording or as of the Company’s initial public offering in May 2015 or at December 31, 2014. The shares of Series A/B/C/D Stock and Series E Stock historically had the right to redemption of their respective class of shares on a date beginning not prior to February 2019 (the “Series E Preferred Stock Redemption Date”). In order to effect each respective redemption, the holders of at least 60% of the voting power of the then outstanding shares of Series D Stock or Series E Stock needed to vote in favor of a Series D or Series E Stock redemption and provide written notice to the Company at lease sixty days prior to the Series E Preferred Stock Redemption Date of such election. The holders of at least a majority in the voting power of the then outstanding shares of the Series A/B/C Stock could then vote in favor of a Series A/B/C Stock redemption, respectively. The holders of at least 66 2/3% of the voting power of the then outstanding shares of Series A Redeemable Convertible Preferred Stock (the “Series A Stock”) could then vote in favor of a Series A Stock redemption. The Series D Stock and Series E Stock redemption value was equal to the Series D Stock and Series E Stock original issue price per share (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like) plus all dividends declared but unpaid thereon together with any accruing dividends accrued but unpaid thereon, whether or not declared with respect to such shares. The Series A/BC/D and Series E Stock redemption value was equal to the respective series original issue price per share (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like) plus all accrued and unpaid dividends with respect to such shares. If the Company did not have sufficient funds or other assets legally available to redeem all shares to be redeemed at any redemption date, it was to redeem as applicable (i) pro rata to Series E Stock, until all shares were redeemed, (ii) pro rata to Series D Stock until all shares were redeemed, (iii) pro rata to Series C Stock, until all shares were redeemed, (iv) pro rata to Series A Stock and Series B Stock, until all shares were redeemed. If any shares to be redeemed remained outstanding, the Company was to redeem the remaining shares in accordance with the previous sentence as soon as sufficient funds were legally available. Due to the redemption feature, the preferred shares were historically recorded as mezzanine equity. Preferred Shares Carrying Value at 5/11/15 Preferred Shares Before IPO Common Shares After IPO Series A Stock $ 1,403,007 1,292,084 38,973 Series B Stock 2,100,149 6,789,712 75,835 Series C-1 Stock 4,569,063 13,242,612 191,406 Series C-2 Stock 2,225,619 9,948,331 93,757 Series D Stock 30,370,273 140,252,678 1,305,984 Series E Stock 7,879,873 45,989,722 428,237 Carrying value, excluding dividends $ 48,547,984 217,515,139 2,134,192 Series D Stock and Series E Stock cumulative dividends 8,808,065 374,632 Total $ 57,356,049 217,515,139 2,508,824 As of the Company’s IPO in May 2015, Series A Stock, Series B Stock, Series C-1 Stock, Series C-2 Stock, Series D Stock and Series E Stock conversion ratios were 0.030, 0.011, 0.014, 0.009, 0.009 and 0.009, respectively, after consideration of the one-for-107.39 reverse split. When converted at May 11, 2015, all of the outstanding preferred shares and cumulative accrued dividends on Series D Stock and Series E Stock were converted into 2,134,192 and 374,632 shares of Common Stock, respectively. The Company has historically accounted for the Series E Warrants as liabilities as such warrants were indexed to shares that could be redeemed for cash outside the control of the Company. The Company allocated the total proceeds first to the Series E Warrants based on their fair value of approximately $1,890,000 and the remainder amounting to approximately $5,665,000 of the proceeds allocated to the Preferred Shares. The fair value of the Series E Warrants was estimated to approximate the fair value of the Series E Stock because of their nominal price. The amount allocated to the Series E Warrants represented a discount to the Preferred Shares and was being accreted using the effective interest method up to the redemption amount from the respective issuance date to redemption date of five years. Accretion for the three and six months ended June 30, 2015 was approximately $40,000 and $128,000, respectively, and accretion for the three and six months ended June 30, 2014 was approximately $137,000 and $137,000, respectively. Upon immediate exercise of the Series E Warrants, the amount recorded as warrant liability was reclassified to Preferred Shares, and issuance costs of $48,384 which had been allocated to the warrants were expensed. The Company was not accreting to the amount resulting from additional liquidation preference rights under the agreement because they were not considered probable at initial recording or at any point between then and May 2015 IPO. The Company additionally analyzed the issuance of Series E Warrants with the Series E Stock, noting there was no resulting beneficial conversion feature. Following the IPO, all outstanding warrants previously exercisable for preferred stock became exercisable for common stock. The previously reported warrant liability associated with the convertible warrants was applied to additional paid-in-capital. The Company’s Series D Stock and Series E Stock accrued cumulative dividends at 8% per annum on the original issue price of $0.2189, whether or not declared by the Board of Directors. In connection with the Company’s Growth Term Loan, the holders of both the Series D Stock and Series E Stock agreed to waive their rights to cash dividends. As a result, only a share dividend, based on the cumulative dividends divided by the original issue price, could be paid upon declaration by the Board of Directors or upon the automatic conversion of the Company’s Preferred Stock. Dividends were being accreted based on the number of days outstanding. At June 30, 2015 and December 31, 2014, the cumulative Series D Stock and Series E Stock dividends were $ 0 The value of the shares of Series A/B/C/D Stock and Series E Stock was recorded at the amount initially received on the date of issuance or upon conversion from debt, less any applicable discounts for warrants and issuance costs, adjusted for the accretion of discounts utilizing the effective interest method up to the redemption amount from the respective issuance date to the Series E Preferred Stock Redemption Date, and the accretion of cumulative dividends. The redemption value for Series A/B/C Stock agrees to the liquidation value presented on face of the balance sheet. The redemption value of Series D Stock and Series E Stock was $0 at June 30, 2015. On January 30, 2015, 51,681 shares of Series E stock were purchased by a convertible note warrant holder for cash consideration of approximately $7,196.

Stockholders Equity (Deficit)

Stockholders Equity (Deficit)	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Stockholders’ Equity (Deficit)	Note 10. Stockholders’ Equity (Deficit) Common Stock The Company amended its certificate of incorporation on May 11, 2015, to decrease the number of authorized shares from 600,000,000 on a post reverse split basis to 200,000,000 shares. The 200,000,000 authorized shares of common stock have a par value of $0.001 per share. As of June 30, 2015, 6,827,414 shares were issued. As of December 31, 2014, 334,003 of the 600,000,000 shares were issued. Each share of common stock is entitled to one vote. All shares of common stock rank equally as to voting and all other matters that the holders are entitled to vote on. The shares of common stock have no preemptive or conversion rights, no redemption or sinking fund provisions, no liability for further call or assessment, and are not entitled to cumulative voting rights. Preferred Stock With the amendment of the Company’s certificate of incorporation the Company has been authorized to issue 10,000,000 shares of preferred stock, each having a par value of $0.001. The preferred stock may be issued from time to time in one or more series with the authorization of the Company’s Board of Directors. The Board of Directors have the ability to determine voting power for each series issued, as well as designation, preferences, and relative, participating, optional or other rights and such qualifications, limitations or restrictions thereof. Stock Option Plan In February 2014, pursuant to the Series E Agreement, the amount of shares reserved under the Company’s 2011 Equity Incentive Plan (the “2011 Plan”) was increased to 20% of the total outstanding shares of the Company calculated on a fully diluted basis. The shares reserved under the 2011 Plan were required to be kept at that percentage with each subsequent equity financing. On May 11, 2015, 940,112 shares were reserved for issuance under the Company’s 2014 Equity Incentive Plan (the “2014 Plan”), including 14,006 shares from the 2011 Plan. As of June 30, 2015, there were 923,031 shares available for issuance under the 2014 Plan. As of June 30, 2015, options to purchase 610,090 shares of Common Stock were outstanding, including 356,050 options that were fully vested. The remaining options vest over 2.7 years. A summary of the Plans’ stock option activity is as follows: Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balance at December 31, 2014 595,577 $ 3.71 7.8 Granted 17,083 – Exercised (1,316 ) 4.24 $ 2,497 Forfeited (1,254 ) 8.41 Balance at June 30, 2015 610,090 3.99 7.4 5,449,483 Vested and expected to vest at June 30, 2015 597,358 3.91 7.3 5,379,404 Exercisable at June 30, 2015 356,050 3.38 6.4 3,386,727 Below is a summary of stock option grant activity and related fair value information for the six months ended June 30, 2015: 2015 Grants Options Granted Exercise Price Fair Value of Common Stock on Date of Grant May 5,000 $ 14.64 $ 14.64 June 12,083 $ 13.83 $ 13.83 Total 17,083 Below is a summary of stock option grant activity and related fair value information for the six months ended June 30, 2014: 2014 Grants Options Granted Exercise Price Fair Value of Common Stock on Date of Grant January 2,094 $ 2.15 $ 2.15 March 249,361 $ 2.15 $ 2.15 May 8,685 $ 2.15 $ 2.15 Total 260,140 As of June 30, 2015, there was total unrecognized compensation expense of $674,100 related to unvested stock options, which the Company expects to recognize over a weighted-average period of approximately 3 years.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2015
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 11. Commitments and Contingencies Legal Matters The Company’s industry is characterized by frequent claims and litigation, including claims regarding intellectual property and product liability. As a result, the Company may be subject to various legal proceedings from time to time. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. Any current litigation is considered immaterial and counter claims have been assessed as remote. Severance Agreements and Retention Plans In October 2012, the Board of Directors and 60% of requisite preferred holders approved a plan to set aside no less than 15% of the proceeds of any sale of the Company to be distributed to the Company’s employees, directors or consultants as designated by the Board of Directors (the “HTG Employee Retention Plan”). The HTG Employee Retention Plan terminated pursuant to its terms upon the closing of the Company’s initial public offering. The Company has entered into employment agreements or other arrangements with certain named executive officers and have adopted an Employee Retention Plan for select participants, which provide salary continuation payments, bonuses and, in certain instances, the acceleration of the vesting of certain equity awards to individuals in the event that the individual is terminated other than for cause, as defined in the applicable agreements or arrangements. Indemnification Agreements In the course of operating our business, the Company has entered into, and continues to enter into, separate indemnification agreements with the Company’s directors and executive officers, in addition to the indemnification provided for in the Company’s amended and restated bylaws. These agreements may require the Company to indemnify its directors and executive officers for certain expenses incurred by a director executive officer in any action or proceeding arising out of their services as one of the Company’s directors or executive officers. Leases The Company leases office and laboratory space under two non-cancelable operating leases in Tucson, Arizona, which were set to expire in November and December 2015, respectively, as of June 30, 2015. Under the terms of the two Tucson leases, the Company had one option to extend the leases for five years at the end of the initial seven year lease term. The Company amended its existing facilities leases in August 2015 to extend the terms for five years and to undergo leasehold improvements to expand and improve its existing research, development, operations and administration office facilities. The lease amendment includes an increase in monthly rents for landlord borne facilities costs of approximately $804,000 over the remaining life of the leases (See Note 14). In addition to these lease term extensions, the Company expects to enter into a construction contract in the third quarter 2015 for the expansion and improvement of its laboratory, manufacturing and office spaces, representing an expected additional commitment of approximately $500,000. The leasehold improvements to both of our leased facilities are expected to be completed in the first half of 2016. Merck Non-Exclusive License Agreement In June 2012, the Company entered into a non-exclusive license agreement with Merck Sharp & Dohme Cor. (“Merck”) whereby the Company agreed to sublicense certain intellectual property related to breast cancer biomarkers with the intent to develop, manufacture and commercialize a diagnostic test utilizing this technology. The Company agreed to pay Merck certain contingent milestone payments between $50,000 and $1,000,000 and future royalties of 3%-6% of sales derived from such products developed that utilize the licensed technology. No amounts have been accrued or paid under this agreement as the Company has not achieved any of the milestone targets or developed any products that utilize the licensed technology.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Note 12. Income Taxes The Company provides for income taxes based upon management’s estimate of taxable income or loss for each respective period. The Company recognizes an asset or liability for the deferred tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts in the financial statements. These temporary differences would result in deductible or taxable amounts in future years, when the reported amounts of the assets are recovered or liabilities are settled, respectively. In each period since inception, the Company has recorded a valuation allowance for the full amount of its net deferred tax assets, as the realization of the net deferred tax assets is uncertain. As a result, the Company has not recorded any Federal or state income tax benefit in the statements of operations. The Company periodically reviews its filing positions for all open tax years in all U.S. Federal, state and international jurisdictions where the Company is or might be required to file tax returns or other required reports. The Company applies a two-step approach to recognizing and measuring uncertain tax positions. The Company evaluates the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation process, if any. The term “more likely than not” means a likelihood of more than 50 percent. Otherwise, the Company may not recognize any of the potential tax benefit associated with the position. The Company recognizes a benefit for a tax position that meets the “more likely than not” criterion at the largest amount of tax benefit that is greater than 50 percent likely of being realized upon its effective resolution. Unrecognized tax benefits involve management’s judgment regarding the likelihood of the benefit being sustained. The final resolution of uncertain tax positions could result in adjustments to recorded amounts and may affect the Company’s results of operations, financial position and cash flows. The Company has not identified any uncertain tax positions at June 30, 2015 or December 31, 2014. The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties at June 30, 2015 and December 31, 2014, respectively, and has not recognized interest or penalties during the three and six months ended June 30, 2015 and 2014, respectively, since there are no material unrecognized tax benefits. Management believes no material change to the amount of unrecognized tax benefits will occur within in the next 12 months.

Related-Party Transactions

Related-Party Transactions	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Related-Party Transactions	Note 13. Related-Party Transactions In March 2014 and July 2013, the Company entered into two separate consulting agreements to assess potential markets for its products with a holder of Series D Stock and Series E Stock. The stockholder was paid $0 and $0 for the three and six months ended June 30, 2015, respectively, and $11,250 and $22,250 for the three and six months ended June 30, 2014, respectively under those agreements. An employee of the stockholder is a member of the Board of Directors. At June 30, 2015, there were no further amounts due under the consulting agreements.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 14. Subsequent Events On August 4, 2015, the Company entered into an amendment to the loan and security agreement with its lenders, Oxford Finance LLC and Silicon Valley Bank. The amendment extended the interest-only payment period through April 1, 2016. It further changed the prepayment fee schedule such that the Company will be obligated to pay a prepayment fee equal to (i) 3% of the principal amount prepaid if the growth term loan is prepaid on or before the first anniversary of the amendment, (ii) 2% of the principal amount repaid if the growth term loan is prepaid after the first anniversary but on or prior to the second anniversary of the amendment and (iii) 1% of the principal amount repaid if the growth term loan is repaid after the second anniversary of the amendment and prior to maturity. The amendment increased the final payment percentage to 4.75%. The amendment also extended the draw period for the second $5.0 million tranche of borrowings available to the Company to the earlier of March 31, 2016 or the occurrence of an event of default, and altered the repayment schedule to allow for repayment of borrowed principal over the course of 30 months beginning April 1, 2016. On August 4, 2015, the Company entered into amendments to its Tucson, Arizona facility lease agreements with its landlord. Pursuant to the terms of these amendments, both lease terms will be extended for five years 500,000 As a result of the amendments the Company’s annual minimum lease payments before common area maintenance charges, which will commence in 2016 and continue through 2020 are as follows: 2016 $ 507,948 2017 510,323 2018 512,734 2019 515,181 2020 517,664

Basis of Presentation and Sum22

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying interim unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect the accounts of the Company as of June 30, 2015. Accordingly they do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America (“GAAP”) for complete financial statements. The accompanying interim unaudited, condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and the results of its operations and cash flows, as of and for the periods presented. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. These financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the fiscal year ended December 31, 2014, included in the Company’s final prospectus supplement filed with the SEC on May 6, 2015, and related to the Company’s Registration Statement on Form S-1/A (File No. 333-201313).
Reverse Stock Split	Reverse Stock Split On April 27, 2015, the Company effected a one-for-107.39 reverse stock split of its common stock. All common share and per common share information has been retroactively adjusted to reflect this reverse stock split. The reverse stock split did not change the number of preferred shares outstanding, only the conversion ratios associated with the preferred shares.
Initial Public Offering	Initial On May 11, 2015, the Company successfully completed its initial public offering (“IPO”), in which the Company sold 3,570,000 shares of common stock at $14.00 per share for total gross proceeds of approximately $50 million. An additional 90,076 shares of common stock were subsequently sold pursuant to the partial exercise by the underwriters of their over-allotment option resulting in additional gross proceeds of approximately $1.3 million. After underwriters’ fees and commissions and other expenses of the offering, the Company’s aggregate net proceeds were approximately $45.4 million. All outstanding shares of the Company’s redeemable convertible preferred stock converted into shares of common stock in connection with the IPO. Following the IPO, there were no shares of preferred stock outstanding.
Liquidity	Liquidity The Company expects that the net proceeds from the IPO and its pre-existing cash and cash equivalents, together with interest thereon, will be sufficient to fund its operations for at least the next 12 months. However, the Company has had recurring operating losses and negative cash flows from operations since its inception. As such, the Company expects to need to raise additional equity or debt capital at some point in the future until its revenue reaches a level sufficient to provide for self-sustaining cash flows. There can be no assurance that additional equity or debt financing will be available on acceptable terms, if at all, or that the Company’s revenue will reach a level sufficient to provide for self-sustaining cash flows. The results of operations for the six months ended June 30, 2015 are not necessarily indicative of the results to be expected for the full fiscal year or any other period.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates include revenue recognition, stock-based compensation expense, the value of the warrant liability, the resolution of uncertain tax positions, income tax valuation allowances, recovery of long-lived assets and provisions for doubtful accounts, inventory obsolescence and inventory valuation. Actual results could materially differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash and cash equivalents. Cash and cash equivalents consist of cash on deposit with financial institutions, money market instruments and high credit quality corporate debt securities purchased with a term of three months or less.
Investments	Investments The Company classifies its securities as available-for-sale, which are reported at estimated fair value with unrealized gains and losses included in accumulated other comprehensive income, net of tax. Realized gains, realized losses and declines in value of securities judged to be other-than-temporary, are included in other income (expense). The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Interest and dividends earned on all securities are included in other income (expense). Investments in securities with maturities of less than one year, or where management’s intent is to use the investments to fund current operations, or to make them available for current operations, are classified as short-term investments. If the estimated fair value of a security is below its carrying value, the Company evaluates whether it is more likely than not that it will sell the security before its anticipated recovery in market value and whether evidence indicating that the cost of the investment is recoverable within a reasonable period of time outweighs evidence to the contrary. The Company also evaluates whether or not it intends to sell the investment. If the impairment is considered to be other-than-temporary, the security is written down to its estimated fair value. In addition, the Company considers whether credit losses exist for any securities. A credit loss exists if the present value of cash flows expected to be collected is less than the amortized cost basis of the security. Other-than-temporary declines in estimated fair value and credit losses are charged against other income (expense). For the period-ended June 30, 2015, the amortized cost of investments held-for-sale approximated its fair value.
Accounts Receivable, net	Accounts Receivable, net Accounts receivable represent valid claims against debtors and have been reported net of an allowance for doubtful accounts of $118,922 and $85,068 at June 30, 2015 and December 31, 2014, respectively. Management reviews accounts receivable to identify where collectability may not be probable based on the specific identification method. Bad debt expense, net of recoveries, was $50,000 and $33,854 for the three and six months ended June 30, 2015, respectively, and $102,467 and $102,467 for the three and six months ended June 30, 2014, respectively.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature. Investments that are classified as available-for-sale are recorded at fair value. The fair value for securities held is determined using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. The carrying amount of the Company’s asset-secured growth capital term loan (the “Growth Term Loan”) and convertible notes were estimated using Level 3 inputs and approximates fair value since the interest rate approximates the market rate for debt securities with similar terms and risk characteristics.
Inventory, net	Inventory, net Inventory, consisting of raw materials and finished goods, is stated at the lower of cost (first-in, first-out) or market. The Company reserves or writes down its inventory for estimated obsolescence, inventory in excess of reasonably expected near term sales or unmarketable inventory, in an amount equal to the difference between the cost of inventory and the estimated market value, based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by the Company, additional inventory write-downs may be required. Inventory impairment charges establish a new cost basis for inventory and charges are not reversed subsequently to income, even if circumstances later suggest that increased carrying amounts are recoverable. For the three and six months ended June 30, 2015, the Company recorded an increase in the inventory reserve of $188,956 and $210,880, respectively, to adjust for estimated shrinkage and excess inventory. For the three and six months ended June 30, 2014, the Company recorded a decrease in the inventory reserve of $536,119 and $536,119, respectively. These amounts were recorded within cost of revenue for each year. During the quarter ended March 31, 2015, the Company determined that the average period of time customers use to evaluate the Company’s equipment generally ranges from 90 to 180 days, and in certain circumstances the evaluation period may need to be extended beyond that period. HTG Edge or HTG EdgeSeq instruments at customer locations under evaluation agreements are included in finished goods inventory. Equipment that is under evaluation for purchase remains in inventory as the Company maintains title to the equipment throughout the evaluation period. If the customer has not completed the purchase of the instrument by the end of the initial evaluation period, the Company will determine whether to extend the evaluation period or have the equipment returned to the Company. However, in no case will the evaluation period exceed one year. If the customer has not purchased the equipment or entered into a reagent agreement with the Company after evaluating for one year, the cost of the equipment is written off to cost of goods sold if the customer is allowed to continue use of the equipment. Prior to January 1, 2015, the Company recorded equipment under evaluation more than 90 days in property and equipment. The Company accordingly has reclassified from property and equipment to inventory field equipment with a net book value of $210,606 at December 31, 2014 under evaluation at that time for longer than 90 days and less than one year.
Property and Equipment, net	Property and Equipment, net Property and equipment are stated at historical cost and depreciated over their useful lives, which range from three to five years, using the straight-line method. Leasehold improvements are amortized using the straight-line method over the lesser of the remaining lease term or the estimated useful life. Field equipment is amortized using the straight-line method over the lesser of the period of the related reagent agreement or the estimated useful life. Depreciation and leasehold improvement amortization expense was $147,916 and $299,409 for the three and six months ended June 30, 2015, respectively, and $117,285 and $225,115 for the three and six months ended June 30, 2014, respectively. Costs incurred in the development and installation of software for internal use are expensed or capitalized, depending on whether they are incurred in the preliminary project stage (expensed), application development stage (capitalized), or post-implementation stage (expensed). Amounts capitalized following project completion are amortized on a straight-line basis over the useful life of the developed asset, which is generally three years. There was no amortization expense for capitalized software costs for the three and six months ended June 30, 2015. Amortization expense for capitalized software costs was $3,896 and $15,583 for the three and six months ended June 30, 2014, respectively.
Stock Issuance Cost	Stock Issuance Costs Certain costs incurred in connection with the issuance of the Company’s Redeemable Convertible Preferred Stock (the “Preferred Stock”) have been deferred and are being accreted. Stock issuance costs have historically been accreted to distributions in excess of capital using the effective interest method. Accretion was $10,969 and $35,046 for the three and six months ended June 30, 2015, respectively, and $186,206 and $208,687 for the three and six months ended June 30, 2014, respectively. Upon automatic conversion of the Preferred Stock to common stock in connection with the closing of the Company’s IPO in May 2015, issuance costs were no longer accreted.
Deferred Financing Costs and Debt Discounts	Deferred Financing Costs and Debt Discounts Certain costs incurred in connection with the Growth Term Loan have been deferred and are being amortized. Debt issuance costs and debt discount are amortized over the term of the Growth Term Loan using the effective interest method. In addition, prior to the IPO, costs incurred in connection with the issuance of notes under the Company’s two note and warrant purchase agreements dated December 30, 2014 (the “Note Agreements”) in February and March 2015 were capitalized and amortized over the term of the Note Agreements using the straight-line accretion method, which approximated the effective interest method in this instance. The Company has recorded approximately $64,105 and $75,131 of deferred financing costs in the accompanying balance sheets as of June 30, 2015 and December 31, 2014, respectively. Deferred financing cost amortization expense for the three and six month periods ended June 30, 2015 was $14,322 and $32,938, respectively. Deferred financing cost amortization was $0 for the three and six months ended June 30, 2014. Amortization of growth term loan discount was $52,512 and $89,032 for the three and six months ended June 30, 2015, respectively, and is included in interest expense in the accompanying condensed statements of operations. Amortization of the Note Agreement discount was $63,490 and $90,222 for the three and six months ended June 30, 2015, respectively, and is included in interest expense in the accompanying condensed statements of operations. The Company compared the value of the common stock issued to settle the debt with the carrying amount of the debt at the IPO closing date of May 2015, net of unamortized discount. The Company recorded a loss on settlement of convertible debt of $705,217, comprised of $651,606 to write off unamortized discount and $53,611 to write off unamortized deferred financing costs relating to the convertible notes which were settled with common stock at the IPO, in the accompanying condensed statements of operations for the three and six months ended June 30, 2015, respectively. There was no growth term loan or convertible note discount accretion for the three and six months ended June 30, 2014.
Deferred Offering Costs	Deferred Offering Costs Deferred offering costs represent legal, accounting and other direct costs related to the IPO, which was completed in May 2015. In accounting for the IPO in May 2015, direct offering costs of approximately $2.3 million were reclassified to additional paid-in capital and are shown, along with underwriters’ fees paid, net against IPO proceeds received. The Company recorded $0 and $1.3 million of deferred offering costs as a non-current asset in the accompanying balance sheet as of June 30, 2015 and December 31, 2014, respectively.
Deferred Revenue	Deferred Revenue Deferred revenue represents cash receipts for products or services to be provided in future periods. When products are delivered or services are rendered, deferred revenue is then recognized as earned.
Revenue Recognition	Revenue Recognition The Company recognizes revenue from the sale of instruments, consumables and related services when the following four basic criteria are met: (1) a contract has been entered into with a customer or persuasive evidence of an arrangement exists, (2) delivery has occurred or services rendered, (3) the fee is fixed and determinable, and (4) collectability is reasonably assured. Sale of instruments and consumables Instrument product revenue is generally recognized upon installation and calibration by our field service engineers, unless the customer has specified any other acceptance criteria. The sale of instruments and related installation and calibration are considered to be one unit of accounting, as instruments are required to be professionally installed and calibrated before use. Installation generally occurs within a week of shipment. Consumables are considered to be separate units of accounting as they are sold separately. Consumables revenue is recognized upon transfer of ownership, which is generally upon shipment. The Company’s standard term and conditions provide that no right of return exists for instruments or consumables. Shipping and handling fees charged to the Company’s customers for instruments and consumables shipped are included in the Statements of Operations as part of product revenue. Shipping and handling costs for sold products shipped to the Company’s customers are included on the Statements of Operations as part of cost of revenue. When a contract involves multiple elements, the items included in the arrangement (deliverables) are evaluated to determine whether they represent separate units of accounting. The Company performs this evaluation at the inception of an arrangement and as each item is delivered in the arrangement. Generally, the Company accounts for a deliverable (or a group of deliverables) separately if the delivered item has stand-alone value to the customer, the customer is given a general right of return relative to the delivered item, and delivery or performance of the undelivered item or service is probable and substantially in the Company’s control. When multiple elements can be separated into separate units of accounting, arrangement consideration is allocated at the inception of the arrangement, based on each deliverables’ relative selling price. All revenue from contracts determined not to have separate units of accounting is recognized based on consideration of the most substantive delivery factor of all the elements in the contract. The Company provides instruments to certain customers under a reagent agreement. Under these agreements, the Company installs instruments in the customer’s facility without a fee and the customer agrees to purchase consumable products at a stated price over the term of the agreement; in some instances the agreements do not contain a minimum purchase requirement. Terms range from several months to multiple years and may automatically renew in several month or multiple year increments unless either party notifies the other in advance that the agreement will not renew. This represents a multiple element arrangement and because all consideration under the reagent agreement is contingent on the sale of consumables, no consideration has been allocated to the instrument and no revenue has been recognized upon installation of the instrument. The Company expects to recover the cost of the instrument under the agreement through the fees charged for consumables, to the extent sold, over the term of the agreement. Revenue is recognized as consumables are shipped. In reagent rental agreements, the Company retains title to the instrument and title is transferred to the customer at no additional charge at the conclusion of the initial arrangement. Because the pattern of revenue from the arrangement cannot be reasonably estimated, the cost of the instrument is amortized on a straight-line basis over the term of the arrangement, unless there is no minimum consumable product purchase in which case the instrument would be expensed as cost of goods sold. Cost to maintain the instrument while title remains with the Company is charged to cost of sales as incurred. Service Revenue For contracts related to custom panel design services and sample processing, the Company utilizes a proportional performance revenue recognition model, under which revenue is recognized as performance occurs based on the relative outputs of the performance that have occurred up to that point in time under the respective agreement. The Company includes all applicable costs incurred related to custom panel design services, including research and development costs and general and administrative expenses, in cost of revenue. The Company also provides contract research services under cost plus fixed fee government contracts. Revenue is recognized under government contracts using the percentage-of-completion method of accounting. Under the percentage-of-completion method, contract research revenue is recognized as the work progresses and services are rendered and costs are incurred. The fixed fee is recognized in proportion to costs incurred compared to total estimated costs. The Company includes all applicable costs incurred from government contracts, including general and administrative expenses on government contracts, in cost of revenue. Anticipated losses, if any, on contracts are charged to earnings as soon as they are identified. Anticipated losses cover all costs allocable to contracts. Revenue arising from claims or change orders is recorded either as income or as an offset against a potential loss only when the amount of the claim can be estimated and its realization is probable. Other Revenue Other revenue includes license and grant revenue. License revenue is generated from the licensing of the Company’s internally developed intellectual property to third parties. The revenue may be generated by nonrefundable up-front payments and license fees, milestone and other contingent payments, or royalties based on sales of commercialized products. Licensing fees are recognized on a straight-line basis over the term of the license agreement for agreements requiring specific continuing performance obligations with deferral of all or a portion of these fees. If it cannot be concluded that a license fee is fixed or determinable at the outset of an arrangement, amounts are recognized as income as payments from third parties become due. No licensing fees were included in other revenue for the three and six months ended June 30, 2015 and 2014. Grant revenue is earned when expenditures relating to the projects under these awards are incurred.
Concentration Risks	Concentration Risks Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and uncollateralized accounts receivable. The Company maintains the majority of its cash balances in the form of cash deposits in bank checking and money market accounts in amounts in excess of federally insured limits. Management believes, based upon the quality of the financial institution, that the credit risk with regard to these deposits is not significant. The Company sells its instruments, consumables, sample processing services, custom panel design services and contract research services primarily to biopharmaceutical companies, academic institutions and molecular labs. The Company routinely assesses the financial strength of its customers and credit losses have been minimal to date. The top three customers accounted for 44%, 7% and 6% of the Company’s revenue for the three months ended June 30, 2015, compared with 12%, 6% and 6% for the three months ended June 30, 2014. The largest two customers accounted for 31% and 15% of the Company’s revenue for the six months ended June 30, 2015. The largest three customers accounted for 15%, 9% and 7% for the six months ended June 30, 2014. The Company derived 12% and 18% of its total revenue from grants and contracts, primarily from one organization during the three and six month periods ended June 30, 2015, respectively. 56% and 37% of total revenue was derived from grants and contracts primarily from one organization, during the three and six month periods ended June 30, 2014, respectively. The largest two customers accounted for approximately 57% and 9% of the Company’s net accounts receivable as of June 30, 2015. One customer accounted for approximately 31% of the Company’s net accounts receivable at December 31, 2014. The Company currently relies on a single vendor to manufacture its HTG Edge processor and reader and HTG EdgeSeq processor and additional single suppliers to supply subcomponents used in the processor. A loss of any of these suppliers could significantly delay the delivery of HTG Edge systems, which in turn would materially affect the Company’s ability to generate revenue.
New Accounting Pronouncements	New Accounting Pronouncements In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing GAAP. The revised revenue standard is effective for public entities for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is currently evaluating the impact of our pending adoption of ASU 2014-09 on our financial statements and has not yet determined the method by which we will adopt the standard. In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Going Concern (“ASU 2014-15”). ASU 2014-15 provides GAAP guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The standard will be effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016. Early application is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. The Company does not believe the adoption of this standard will have a significant impact on the Company’s financial statements. In April 2015, the FASB issued an accounting standards update entitled “ASU 2015-03, Interest – Imputation of Interest: Simplifying the presentation of Debt Issuance Costs”. The standard requires entities to present debt issuance costs on the balance sheet as a direct deduction from the related debt liability rather than as an asset, and the amortization is reported as interest expense. The result of application of this guidance would be to reduce the deferred financing costs balance, with a corresponding reduction to the long term liabilities to which the debt issuance costs relate in the condensed balance sheets. The standard does not affect recognition and measurement of debt issuance costs. The Company expects to adopt ASU 2015-03 on January 1, 2016. In July 2015, the FASB issued an accounting standards update entitled “ASU 2015-11, Inventory: Simplifying the Measurement of Inventory”. The standard requires inventory within the scope of the ASU to be measured using the lower of cost and net realizable value. The changes apply to all types of inventory, except those measured using LIFO or retail inventory method, and are intended to more clearly articulate the requirements for the measurement and disclosure of inventory and to simplify the accounting for inventory by eliminating the notions of replacement cost and net realizable value less a normal profit margin. The standard will be effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016. The Company does not believe the adoption of this standard will have a significant impact on the Company’s financial statements.

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory, net of reserves, consisted of the following as of the date indicated: June 30, December 31, 2015 2014 Raw materials $ 228,954 $ 174,150 Work in process — — Finished goods 2,183,139 1,511,664 $ 2,412,093 $ 1,685,814

Fair Value of Financial Instr24

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table provides information about the Company’s financial assets and liabilities measured at fair value on a recurring basis at June 30, 2015 and December 31, 2014, respectively: Balance at June 30, 2015 Level 1 Level 2 Level 3 Balance at December 31, 2014 Level 1 Level 2 Level 3 Asset included in: Cash and cash equivalents Money market securities $ 9,666,594 $ 9,666,594 $ — $ 3,608,890 $ 3,608,890 $ — $ — Corporate debt securities $ 1,499,462 $ — $ 1,499,462 $ — $ — $ — $ — $ — Investments at fair value U.S. government obligations $ 3,307,680 $ 3,307,680 $ — $ — $ — $ — $ — $ — U.S. government agency obligations $ 14,717,062 $ — $ 14,717,062 $ — $ — $ — $ — $ — Corporate debt securities $ 14,844,827 $ — $ 14,844,827 $ — $ — $ — $ — $ — Liabilities: Growth Term Loan warrants $ — $ — $ — $ — $ 301,508 $ — $ — $ 301,508 Preferred Stock warrants $ — $ — $ — $ — $ 429,035 $ — $ — $ 429,035
Summary of Fair Value Assessment of Warrant Liability Inputs using Black Sholes Option Pricing Model	The December 31, 2014 fair value assessments used the Black-Sholes option pricing model using the following assumptions: December 31, 2014 Fair value of Series B/C/D Stock and Series E Stock shares on grant date or measurement date $0.14 - $0.22 Exercise price $0.01 - $0.346 Expected risk-free interest rate 1.20% Expected volatility 70% Expected term 4.1 years Expected dividend yield 0 - 8%
Reconciliation of Beginning and Ending Liabilities Measured at Fair Value on Recurring Basis	A reconciliation of the beginning and ending liabilities measured at fair value on a recurring basis using Level 3 inputs for June 30, 2015 and June 30, 2014 are as follows: June 30, 2015 June 30, 2014 Beginning balance $ 730,543 $ 44,120 Issuance of Series E Preferred Stock Warrants — 1,890,000 Exercise of Series E Preferred Stock Warrants (4,116 ) (1,890,000 ) Exercise of Series D Preferred Stock Warrants (91,798 ) — Reclassification of Series C-2 Warrants to Common Stock Warrants (555 ) — Reclassification of Growth Term Loan Warrants to Common Warrants (229,550 ) — Issuance of Convertible Note Warrants 741,828 — Reclassification of Convertible Note Warrants to Common Stock Warrants (1,386,035 ) — Change in preferred stock warrant valuation 239,683 56,322 Ending balance $ — $ 100,442

Debt Obligations (Tables)

Debt Obligations (Tables)	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Principal Repayments Due Under Term Loan	The principal repayments due under the term loan as of June 30, 2015, are as follows: 2015 $ — 2016 3,059,068 2017 4,393,103 2018 3,547,829 Total Growth Term Loan payments 11,000,000 Less discount (447,799 ) Plus final fee premium 115,292 Total Growth Term Loan, net $ 10,667,493

Other Agreements (Tables)

Other Agreements (Tables)	6 Months Ended
	Jun. 30, 2015
Other Agreements [Abstract]
Schedule of Remaining Payments Due	The remaining payments due to NuvoGen at June 30, 2015, are as follows: 2015 $ — 2016 543,750 2017 800,000 2018 400,000 2019 400,000 2020 and beyond 7,098,743 $ 9,242,493

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Reconciliation of Numerator and Denominator Used in Computing Basic and Diluted Net Loss per Share	The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss per share: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Numerator: Net loss $ (6,452,342 ) $ (3,684,826 ) $ (10,540,477 ) $ (6,512,416 ) Accretion of stock issuance costs (10,969 ) (186,206 ) (35,046 ) (208,687 ) Accretion of discount on Series E warrants (40,146 ) (85,717 ) (127,616 ) (137,094 ) Series E and D, preferred stock dividends (367,350 ) (828,125 ) (1,165,932 ) (1,568,762 ) Net loss attributable to common stockholders $ (6,870,807 ) $ (4,784,874 ) $ (11,869,071 ) $ (8,426,959 ) Denominator: Weighted-average common shares outstanding -basic and diluted 3,973,055 96,440 2,163,295 96,426
Outstanding Options, Warrants and Preferred Stock Excluded from Computation of Diluted Net Loss per Share	The following outstanding options, warrants and preferred stock were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Six Months Ended June 30, 2015 2014 Options to purchase common stock 610,090 553,622 Convertible preferred stock (as converted) — 2,353,163 Convertible preferred stock warrants (as converted) — 27,534 Common stock warrant 170,587 931

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Jun. 30, 2015
Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants [Abstract]
Summary of Outstanding Warrants	Security Number of Preferred and Common Warrants at December 31, 2014 Number of Common Warrants at June 30, 2015 Exercise Price/Share Expiration Date Series C-1 redeemable convertible preferred stock warrants 1,290,350 — $ 37.16 2016-2017 Series C-2 redeemable convertible preferred stock warrants 157,912 1,488 24.23 2015 Series D redeemable convertible preferred stock warrants 769,059 — 1.07 2020 Series E redeemable convertible preferred stock warrants 2,512,562 23,396 23.51 2024 Convertible note warrants — 144,772 14.00 2022 Common stock warrants 931 931 6.45 2019

Redeemable Convertible Prefer29

Redeemable Convertible Preferred Stock (Tables)	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Summary of Preferred Stock	Preferred Shares Carrying Value at 5/11/15 Preferred Shares Before IPO Common Shares After IPO Series A Stock $ 1,403,007 1,292,084 38,973 Series B Stock 2,100,149 6,789,712 75,835 Series C-1 Stock 4,569,063 13,242,612 191,406 Series C-2 Stock 2,225,619 9,948,331 93,757 Series D Stock 30,370,273 140,252,678 1,305,984 Series E Stock 7,879,873 45,989,722 428,237 Carrying value, excluding dividends $ 48,547,984 217,515,139 2,134,192 Series D Stock and Series E Stock cumulative dividends 8,808,065 374,632 Total $ 57,356,049 217,515,139 2,508,824

Stockholders Equity (Deficit) (

Stockholders Equity (Deficit) (Tables)	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Summary of Stock Option Plans Activity	A summary of the Plans’ stock option activity is as follows: Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balance at December 31, 2014 595,577 $ 3.71 7.8 Granted 17,083 – Exercised (1,316 ) 4.24 $ 2,497 Forfeited (1,254 ) 8.41 Balance at June 30, 2015 610,090 3.99 7.4 5,449,483 Vested and expected to vest at June 30, 2015 597,358 3.91 7.3 5,379,404 Exercisable at June 30, 2015 356,050 3.38 6.4 3,386,727
Summary of Stock Option Grant Activity and Fair Value Information	Below is a summary of stock option grant activity and related fair value information for the six months ended June 30, 2015: 2015 Grants Options Granted Exercise Price Fair Value of Common Stock on Date of Grant May 5,000 $ 14.64 $ 14.64 June 12,083 $ 13.83 $ 13.83 Total 17,083 Below is a summary of stock option grant activity and related fair value information for the six months ended June 30, 2014: 2014 Grants Options Granted Exercise Price Fair Value of Common Stock on Date of Grant January 2,094 $ 2.15 $ 2.15 March 249,361 $ 2.15 $ 2.15 May 8,685 $ 2.15 $ 2.15 Total 260,140

Subsequent Events (Tables)

Subsequent Events (Tables)	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Minimum Lease Payments Before Common Area Maintenance Charges	As a result of the amendments the Company’s annual minimum lease payments before common area maintenance charges, which will commence in 2016 and continue through 2020 are as follows: 2016 $ 507,948 2017 510,323 2018 512,734 2019 515,181 2020 517,664

Description of Business - Addit

Description of Business - Additional Information (Details) - Segment	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Significant Accounting Policies [Line Items]
Number of operating segments			1
Sales Revenue, Net | Customer Concentration Risk | Customers Located Outside Of United States
Significant Accounting Policies [Line Items]
Sales revenue percentage	2.00%	13.00%	3.00%	27.00%

Basis of Presentation and Sum33

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)	May. 11, 2015USD ($)$ / sharesshares	Apr. 27, 2015	May. 31, 2015USD ($)	Jun. 30, 2015USD ($)Customershares	Jun. 30, 2014USD ($)Customer	Jun. 30, 2015USD ($)Customershares	Jun. 30, 2014USD ($)Customer	Dec. 31, 2014USD ($)Customershares
Significant Accounting Policies [Line Items]
Reverse stock split of common stock		0.0093
Common stock, at the initial public offering price per shares | $ / shares	$ 14
Gross proceeds from initial public offering						$ 47,654,190
Preferred stock, shares outstanding | shares				0		0		0
Maturity period of investments						less than one year
Allowance for Doubtful Accounts Receivable				$ 118,922		$ 118,922		$ 85,068
Bad debt expense, net of recoveries				50,000	$ 102,467	33,854	$ 102,467
Change in inventory valuation reserves				188,956	(536,119)	210,880	(536,119)
Reclassified equipment with a net book value								210,606
Depreciation and leasehold improvement amortization expense				147,916	117,285	299,409	225,115
Amortization expense for capitalized software costs				0	3,896	0	15,583
Accretion of preferred stock issuance costs				10,969	186,206	35,046	208,687
Deferred financing costs				64,105		64,105		75,131
Deferred financing cost amortization expense				14,322	0	32,938	0
Debt instrument, amortization expense				51,180	47,184	177,751	94,684
Amortization of discount on convertible notes				63,490		90,222
Loss on settlement of convertible notes				705,217		705,217
Accretion of discount on NuvoGen obligation						177,751	94,684
Write off of deferred financing costs						53,611
Write off unamortized debt discount						651,606
Deferred offering costs, noncurrent				0		0		$ 1,300,000
Licenses revenue fees				$ 0	$ 0	$ 0	$ 0
Sales Revenue, Net | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer				3	3	2	3
Sales Revenue, Net | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage				44.00%	12.00%	31.00%	15.00%
Sales Revenue, Net | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage				7.00%	6.00%	15.00%	9.00%
Sales Revenue, Net | Customer Concentration Risk | Customer Three
Significant Accounting Policies [Line Items]
Sales revenue percentage				6.00%	6.00%		7.00%
Accounts Receivable | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer						2		1
Accounts Receivable | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage						57.00%		31.00%
Accounts Receivable | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage						9.00%
Revenue from grants and contracts | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Sales revenue percentage				12.00%	56.00%	18.00%	37.00%
Growth Term Loan A
Significant Accounting Policies [Line Items]
Debt instrument, amortization expense				$ 52,512	$ 0	$ 89,032	$ 0
Accretion of discount on NuvoGen obligation				0		0
Convertible Notes
Significant Accounting Policies [Line Items]
Accretion of discount on NuvoGen obligation				$ 0		$ 0
Software and Software Development Costs
Significant Accounting Policies [Line Items]
Long-term asset, estimated life						3 years
Minimum
Significant Accounting Policies [Line Items]
Long-term asset, estimated life						3 years
Maximum
Significant Accounting Policies [Line Items]
Long-term asset, estimated life						5 years
IPO
Significant Accounting Policies [Line Items]
Issuance of common stock from initial public offering, shares | shares	3,570,000
Common stock, at the initial public offering price per shares | $ / shares	$ 14
Gross proceeds from initial public offering	$ 50,000,000
Net proceeds from initial public offering after underwriters' fees, commissions and offering costs	$ 45,400,000
Preferred stock, shares outstanding | shares				0		0
Reclassification of additional paid in capital with direct offering costs			$ 2,300,000
Over-Allotment Option
Significant Accounting Policies [Line Items]
Issuance of common stock from initial public offering, shares | shares	90,076
Proceeds from issuance of common stock	$ 1,300,000

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 228,954	$ 174,150
Finished goods	2,183,139	1,511,664
Inventory, net	$ 2,412,093	$ 1,685,814

Fair Value of Financial Instr35

Fair Value of Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Cash and Cash Equivalents | Money Market Securities
Asset included in:
Financial Assets	$ 9,666,594	$ 3,608,890
Cash and Cash Equivalents | Corporate Debt Securities
Asset included in:
Financial Assets	1,499,462
Investments at Fair Value | Corporate Debt Securities
Asset included in:
Financial Assets	14,844,827
Investments at Fair Value | US Government Obligations
Asset included in:
Financial Assets	3,307,680
Investments at Fair Value | US Government Agency Obligations
Asset included in:
Financial Assets	14,717,062
Level 1 | Cash and Cash Equivalents | Money Market Securities
Asset included in:
Financial Assets	9,666,594	3,608,890
Level 1 | Investments at Fair Value | US Government Obligations
Asset included in:
Financial Assets	3,307,680
Level 2 | Cash and Cash Equivalents | Corporate Debt Securities
Asset included in:
Financial Assets	1,499,462
Level 2 | Investments at Fair Value | Corporate Debt Securities
Asset included in:
Financial Assets	14,844,827
Level 2 | Investments at Fair Value | US Government Agency Obligations
Asset included in:
Financial Assets	$ 14,717,062
Preferred Stock Warrants
Liabilities:
Financial Liabilities		429,035
Preferred Stock Warrants | Level 3
Liabilities:
Financial Liabilities		429,035
Warrant
Liabilities:
Financial Liabilities		301,508
Warrant | Level 3
Liabilities:
Financial Liabilities		$ 301,508

Fair Value of Financial Instr36

Fair Value of Financial Instruments - Additional Information (Details)	Jun. 30, 2015shares
Fair Value Disclosures [Abstract]
Class of Warrant or Right, Outstanding	0

Fair Value of Financial Instr37

Fair Value of Financial Instruments - Summary of Fair Value Assessment of Warrant Liability Inputs using Black Sholes Option Pricing Model (Details) - Dec. 31, 2014 - $ / shares	Total	Total
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value of Series B/C/D Stock and Series E Stock shares on grant date or measurement date	$ 0.13	$ 0.13
Expected risk-free interest rate	1.60%	1.20%
Expected volatility	75.00%	70.00%
Expected term	7 years	4 years 1 month 6 days
Expected dividend yield	0.00%
Minimum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value of Series B/C/D Stock and Series E Stock shares on grant date or measurement date	$ 0.14	$ 0.14
Exercise price	0.01	$ 0.01
Expected dividend yield		0.00%
Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value of Series B/C/D Stock and Series E Stock shares on grant date or measurement date	0.22	$ 0.22
Exercise price	$ 0.346	$ 0.346
Expected dividend yield		8.00%

Fair Value of Financial Instr38

Fair Value of Financial Instruments - Reconciliation of Beginning and Ending Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 730,543	$ 44,120
Issuance of warrants	741,828
Change in preferred stock warrant valuation	239,683	56,322
Ending balance		100,442
Series E Preferred Stock Warrants
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Issuance of warrants		1,890,000
Exercise of warrants	(4,116)	$ (1,890,000)
Series D Preferred Stock Warrants
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Exercise of warrants	(91,798)
Series C-2 Warrants
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Reclassification of warrants	(555)
Convertible Note Warrants
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Reclassification of warrants	(1,386,035)
Growth Term Loan
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Reclassification of warrants	$ (229,550)

Debt Obligations - Additional I

Debt Obligations - Additional Information (Details)	Dec. 30, 2014USD ($)AgreementFuture$ / sharesshares	May. 31, 2015USD ($)$ / sharesshares	Aug. 31, 2014USD ($)Institution$ / sharesshares	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Dec. 31, 2014USD ($)$ / shares	Aug. 22, 2014USD ($)
Debt Obligations [Line Items]
Debt instrument, amortization expense				$ 51,180	$ 47,184	$ 177,751	$ 94,684
Financing costs						75,523
Number of convertible promissory note agreements | Agreement	2
Issuance of common stock from initial public offering						45,357,111
Investor equity with warrants percentage	80.00%
Outstanding convertible notes payable	$ 0
Fair value of warrants								$ 741,828
Conversion of stock, amount converted						4,544,384
Percentage of possible outcomes in debt note agreements issued		50.00%
Write off unamortized debt discount and deferred financing costs				705,217		705,217
Convertible Debt
Debt Obligations [Line Items]
Amortization of warrant discount				57,551	0	89,557	0
Series E Stock
Debt Obligations [Line Items]
Class of warrant or right per share price | $ / shares								$ 0.2189
Growth Term Loan
Debt Obligations [Line Items]
Number of loan lending institutions | Institution			2
Financing costs			$ 100,000
Growth Term Loan | Series E Stock
Debt Obligations [Line Items]
Financial institution warrant issued, share | shares			2,512,562
Class of warrant or right per share price | $ / shares			$ 0.2189
Warrants expiration date			Aug. 22, 2024
Growth Term Loan A
Debt Obligations [Line Items]
Term loan payable									$ 11,000,000
Debt instrument, amortization expense				52,512	$ 0	$ 89,032	$ 0
Debt instrument, fixed rate			8.50%
Monthly periodic payment			$ 408,296
Growth Term Loan A | Maximum
Debt Obligations [Line Items]
Debt instrument, maturity date						Sep. 30, 2018
Growth Term Loan A | Minimum
Debt Obligations [Line Items]
Debt instrument, maturity date						Sep. 30, 2015
Growth Term Loan B
Debt Obligations [Line Items]
Term loan payable			5,000,000
Debt issuance costs			$ 300,000
Convertible Notes
Debt Obligations [Line Items]
Debt conversion, converted instrument, rate	80.00%
Extinguishment of debt as percentage of principal amount	80.00%
Debt Instrument, Convertible, Terms of Conversion Feature						Under each of the Note Agreements, the failure of a principal or major participating investor to invest their committed amount at each of the closings resulted in the conversion of a percentage of the investor’s preferred shares into common shares at the applicable conversion rates in effect pursuant to the Company’s restated certificate of incorporation. Under the first Note Agreement, failure of a principal investor to purchase their committed amount resulted in the conversion of their entire holdings of preferred stock into common stock, at conversion rates then in effect. Under the second Note Agreement, up to 80% of the total preferred stock held by such investor will be converted into common stock, at conversion rates then in effect. In addition, failure to purchase the full committed amount in any closing will result in the termination of the applicable investor’s warrants, in whole or in part, and the forgiveness and extinguishment of 80% of the aggregate principal amount of the applicable investor’s outstanding notes, if any. In the event the Company sold new shares of stock in a qualified initial public offering or preferred stock in a private placement, an investor’s failure to participate in the subsequent equity financing, in an amount equal to their applicable remaining committed amount under the Note Agreements, would result in the conversion of up to 80% of the non-participating investor’s aggregate preferred stock holding as of the closing date of the subsequent equity financing, along with a reduction of up to 80% of the non-participating investor’s warrants. Pursuant to the provisions of the second Note Agreement, certain preferred shares were optionally converted into common stock as of December 30, 2014.
Fair value of warrants				$ 741,828		$ 741,828
Settlement of outstanding principal and accrued interest on convertible notes by issuance of common stock, shares | shares		324,591
Conversion price per share | $ / shares		$ 14
Conversion of stock, amount converted		$ 4,500,000
Convertible Notes | Minimum | Private Placement
Debt Obligations [Line Items]
Proceeds from sale of preferred stock, net of issuance costs	$ 20,000,000
Convertible Note One
Debt Obligations [Line Items]
Debt instrument, fixed rate	8.00%
Debt instrument, maturity date						Mar. 31, 2016
Issuance of common stock from initial public offering	$ 7,339,165
Number of future issued to existing investors | Future	5
Closing value	$ 1,500,000
Number of days of notice to participating investors	10 days
Convertible note draws		4,500,000
Convertible Note One | Series E Stock
Debt Obligations [Line Items]
Financial institution warrant issued, share | shares	5,029,114
Class of warrant or right per share price | $ / shares	$ 0.2189
Convertible Note Two
Debt Obligations [Line Items]
Debt instrument, fixed rate	8.00%
Debt instrument, maturity date						Mar. 31, 2016
Issuance of common stock from initial public offering	$ 6,203,971
Number of future issued to existing investors | Future	4
Closing value	$ 1,703,971
Number of days of notice to participating investors	10 days
Conversion percentage	80.00%
Convertible note draws		$ 0
Convertible Note Two | Series E Stock
Debt Obligations [Line Items]
Financial institution warrant issued, share | shares	4,282,472
Class of warrant or right per share price | $ / shares	$ 0.2189

Debt Obligations - Principal Re

Debt Obligations - Principal Repayments Due Under Term Loan (Details) - Term Loan	Jun. 30, 2015USD ($)
Debt Instrument [Line Items]
2,016	$ 3,059,068
2,017	4,393,103
2,018	3,547,829
Total Growth Term Loan payments	11,000,000
Less discount	(447,799)
Plus final fee premium	115,292
Total Growth Term Loan, net	$ 10,667,493

Other Agreements - Additional I

Other Agreements - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Other Agreements [Line Items]
Upfront consideration paid in exchange of common stock			600,000
Remaining cash consideration to be paid	$ 15,000,000		$ 15,000,000
Percentage on annual revenues for cash consideration to be paid			6.00%
Discount rate used to calculate asset purchase obligation			2.50%
Payments on obligation	0	$ 112,500	$ 0	$ 225,000
Accretion of discount on Nuvogen obligation	51,180	47,184	177,751	94,684
Research and development	953,222	$ 865,540	$ 1,641,437	$ 1,723,023
Agreement expiration date			Oct. 31, 2019
Description on termination of agreement			The Company may terminate the agreement at any time upon 90 days’ written notice and may terminate any development plan under the agreement upon 30 days’ prior written notice. Illumina may terminate the agreement upon 30 days’ prior written notice if the Company undergoes certain changes of control or immediately if the Company fails to select a testing field for an IVD test kit within 24 months following the date of the agreement. Either party may terminate the agreement upon the other party’s material breach of the agreement that remains uncured for 30 days, or upon the other party’s bankruptcy
Illumina, Inc. Agreement
Other Agreements [Line Items]
Aggregate payment upon achievement of specified regulatory milestones	1,000,000		$ 1,000,000
Research and development			0
Growth Term Loan
Other Agreements [Line Items]
Minimum payments of pledged intangible assets due in 2014	868,750		868,750
Minimum payments of pledged intangible assets due in 2015	868,750		868,750
Minimum payments of pledged intangible assets due in first quarter of 2016	868,750		868,750
Minimum payments of pledged intangible assets due in second quarter of 2016	0		0
NuvoGen
Other Agreements [Line Items]
Convertible notes and related debt discount	$ 386,883		$ 386,883		$ 564,634

Other Agreements - Schedule of

Other Agreements - Schedule of Remaining Payments Due (Details) - NuvoGen Asset Purchase Agreement	Jun. 30, 2015USD ($)
Purchase Obligation Fiscal Year Maturity [Line Items]
2,015	$ 0
2,016	543,750
2,017	800,000
2,018	400,000
2,019	400,000
2020 and beyond	7,098,743
Total	$ 9,242,493

Net Loss per Share - Reconcilia

Net Loss per Share - Reconciliation of Numerator and Denominator Used in Computing Basic and Diluted Net Loss per Share (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Numerator:
Net loss	$ (6,452,342)	$ (3,684,826)	$ (10,540,477)	$ (6,512,416)
Accretion of stock issuance costs	(10,969)	(186,206)	(35,046)	(208,687)
Series E and D, preferred stock dividends	(367,350)	(828,125)	(1,165,932)	(1,568,762)
Net loss attributable to common stockholders	$ (6,870,807)	$ (4,784,874)	$ (11,869,071)	$ (8,426,959)
Denominator:
Weighted-average common shares outstanding -basic and diluted	3,973,055	96,440	2,163,295	96,426
Series E Warrants
Numerator:
Accretion of Series E warrant discount	$ 40,146	$ 85,717	$ 127,616	$ 137,094

Net Loss per Share - Outstandin

Net Loss per Share - Outstanding Options, Warrants and Preferred Stock Excluded from Computation of Diluted Net Loss per Share (Detail) - shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Convertible preferred stock (as converted)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share		2,353,163
Options to purchase common stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	610,090	553,622
Warrant | Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	170,587	931
Warrant | Convertible preferred stock (as converted)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share		27,534

Warrants - Additional Informati

Warrants - Additional Information (Details) - USD ($)	May. 11, 2015	Jan. 15, 2015	Aug. 22, 2014	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	May. 31, 2015
Class Of Warrant Or Right [Line Items]
Share price					$ 0.13				$ 0.13
Expected risk-free interest rate					1.60%				1.20%
Expected volatility					75.00%				70.00%
Expected term					7 years				4 years 1 month 6 days
Expected dividend yield					0.00%
Fair value of warrants					$ 741,828				$ 741,828
Common stock, at the initial public offering price per shares	$ 14
Preferred stock, shares issued				0	0		0		0
Class of Warrant or Right, Outstanding				0			0
Proceeds from exercise of E warrants							$ 8,948
Fair value of preferred stock warrant liability				$ 0	$ 730,543		0		$ 730,543
Loss from change in stock warrant valuation				$ (628,643)		$ (56,322)	$ (239,683)	$ (56,322)
IPO
Class Of Warrant Or Right [Line Items]
Common stock, at the initial public offering price per shares	$ 14
Series E Stock
Class Of Warrant Or Right [Line Items]
Share price			$ 0.31
Warrants exercise price			$ 0.2189
Expected risk-free interest rate			1.60%
Expected volatility			70.00%
Expected term			4 years 6 months
Expected dividend yield			8.00%
Series C-1 Redeemable Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Warrants exercise price				$ 37.16			$ 37.16
Preferred stock warrants forfeited and cancelled	1,290,350
Class of Warrant or Right, Outstanding					1,290,350				1,290,350
Series C-2 Redeemable Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Warrants exercise price				$ 24.23			$ 24.23
Class of Warrant or Right, Outstanding					157,912				157,912
Series C-2 Redeemable Convertible Preferred Stock | IPO
Class Of Warrant Or Right [Line Items]
Warrants issued to acquire shares	1,488
Warrants exercise price	$ 24.23
Class of Warrant or Right, Outstanding				1,488			1,488
Series D Preferred Stock
Class Of Warrant Or Right [Line Items]
Warrants exercise price				$ 1.07			$ 1.07
Common stock, at the initial public offering price per shares				$ 14			$ 14
Preferred stock, shares issued				723,050			723,050
Class of Warrant or Right, Outstanding				769,059	769,059		769,059		769,059
Proceeds from exercise of E warrants							$ 1,752
Conversion of stock, shares issued	6,729
Series E Loan Warrants
Class Of Warrant Or Right [Line Items]
Warrants issued to acquire shares			2,512,562							23,396
Warrants exercise price			$ 0.2189							$ 23.51
Warrants expiration date							Aug. 22, 2024
Warrants exercise price			$ 0.12
Fair value of warrants			$ 301,507		$ 301,507				$ 301,507
Series E Loan Warrants | IPO
Class Of Warrant Or Right [Line Items]
Warrants issued to acquire shares	23,396
Warrants exercise price	$ 14
Convertible Note Warrants
Class Of Warrant Or Right [Line Items]
Warrants issued to acquire shares		9,311,586
Warrants exercise price		$ 0.2189		$ 14			$ 14
Warrants expiration date							Jan. 15, 2022
Aggregate consideration		$ 1,354
Convertible Note Warrants | IPO
Class Of Warrant Or Right [Line Items]
Warrants issued to acquire shares	144,772
Warrants exercise price	$ 14
Class of Warrant or Right, Outstanding				144,772			144,772

Warrants -Summary of Outstandin

Warrants -Summary of Outstanding Warrants (Details) - $ / shares	6 Months Ended
	Jun. 30, 2015	May. 11, 2015	Jan. 15, 2015	Dec. 31, 2014
Class Of Warrant Or Right [Line Items]
Number of Warrants	0
Convertible Note Warrants
Class Of Warrant Or Right [Line Items]
Exercise Price/Share	$ 14		$ 0.2189
Expiration Date	2,022
Convertible Note Warrants | IPO
Class Of Warrant Or Right [Line Items]
Number of Warrants	144,772
Exercise Price/Share		$ 14
Common Stock Warrants
Class Of Warrant Or Right [Line Items]
Number of Warrants				931
Exercise Price/Share	$ 6.45
Expiration Date	2,019
Common Stock Warrants | IPO
Class Of Warrant Or Right [Line Items]
Number of Warrants	931
Series C-1 Redeemable Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Number of Warrants				1,290,350
Exercise Price/Share	$ 37.16
Expiration Date	2,016
Expiration Date	2,017
Series C-2 Redeemable Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Number of Warrants				157,912
Exercise Price/Share	$ 24.23
Expiration Date	2,015
Series C-2 Redeemable Convertible Preferred Stock | IPO
Class Of Warrant Or Right [Line Items]
Number of Warrants	1,488
Exercise Price/Share		$ 24.23
Series D Redeemable Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Number of Warrants	769,059			769,059
Exercise Price/Share	$ 1.07
Expiration Date	2,020
Series E Redeemable Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Number of Warrants				2,512,562
Exercise Price/Share	$ 23.51
Expiration Date	2,024
Series E Redeemable Convertible Preferred Stock | IPO
Class Of Warrant Or Right [Line Items]
Number of Warrants	23,396

Redeemable Convertible Prefer47

Redeemable Convertible Preferred Stock - Additional Information (Details)	Apr. 27, 2015	Mar. 31, 2014USD ($)$ / sharesshares	Feb. 04, 2014USD ($)$ / sharesshares	Jun. 30, 2015USD ($)$ / sharesshares	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)$ / sharesshares	Jun. 30, 2014USD ($)	Dec. 31, 2014USD ($)$ / sharesshares	May. 11, 2015shares	Jan. 30, 2015USD ($)shares
Class Of Stock [Line Items]
Common stock, shares authorized			600,000,000	200,000,000		200,000,000		600,000,000
Preferred stock, shares authorized			472,083,383
Common stock, conversion basis	0.0093
Preferred stock par value, per share | $ / shares				$ 0.001		$ 0.001		$ 0.001
Outstanding convertible preferred stock				2,134,192		2,134,192			2,134,192
Reverse stock split						one-for-107.39
Fair value of warrants | $								$ 741,828
Preferred Stock
Class Of Stock [Line Items]
Fair value of warrants | $				$ 5,665,000		$ 5,665,000
Accretion of Series E warrant discount | $				$ 40,000	$ 137,000	$ 128,000	$ 137,000
Series E Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Convertible preferred stock, shares authorized			99,132,024
Convertible preferred stock, price per share | $ / shares		$ 0.2189	$ 0.2189	$ 0.2189		$ 0.2189
Preferred stock, shares authorized				0		0		185,046,445
Issuance of preferred stock, net of issuance cost, shares		354,062	34,099,476
Warrants exercise price | $ / shares				$ 23.51		$ 23.51
Common stock, conversion basis		1				0.009
Preferred stock par value, per share | $ / shares				$ 0.001		$ 0.001
Liquidation preference						The Series D Stock and Series E Stock liquidation preference was equal to two times the original issue price of the Series D Stock or Series E Stock, respectively, plus any accrued but unpaid dividends whether or not declared.
Outstanding convertible preferred stock				428,237		428,237
Preferred stock cumulative dividend percentage						8.00%
Preferred stock redemption value | $				$ 0		$ 0
Stock purchased by convertible note warrant holder, shares										51,681
Stock purchased by convertible note warrant holder for cash consideration | $										$ 7,196
Series A Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Preferred stock, shares authorized				0		0		1,292,084
Common stock, conversion basis						0.030
Preferred stock par value, per share | $ / shares				$ 0.001		$ 0.001
Stock holders voting percentage required for stock redemption						66.67%
Outstanding convertible preferred stock				38,973		38,973
Series B Preferred Stock
Class Of Stock [Line Items]
Preferred stock, shares authorized				0		0		11,919,624
Common stock, conversion basis						0.011
Preferred stock par value, per share | $ / shares				$ 0.001		$ 0.001
Outstanding convertible preferred stock				75,835		75,835
Series C Preferred Stock
Class Of Stock [Line Items]
Preferred stock par value, per share | $ / shares				$ 0.001		$ 0.001
Series D Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Convertible preferred stock, price per share | $ / shares				$ 0.2189		$ 0.2189
Preferred stock, shares authorized				0		0		237,031,908
Warrants exercise price | $ / shares				$ 1.07		$ 1.07
Common stock, conversion basis						0.009
Preferred stock par value, per share | $ / shares				$ 0.001		$ 0.001
Liquidation preference						The Series D Stock and Series E Stock liquidation preference was equal to two times the original issue price of the Series D Stock or Series E Stock, respectively, plus any accrued but unpaid dividends whether or not declared.
Outstanding convertible preferred stock				1,305,984		1,305,984
Preferred stock cumulative dividend percentage						8.00%
Preferred stock cumulative dividends | $						$ 0
Preferred stock redemption value | $				$ 0		$ 0
A B C D Stock And Series E Stock
Class Of Stock [Line Items]
Stock holders voting percentage required for stock redemption						60.00%
Series C-1
Class Of Stock [Line Items]
Common stock, conversion basis						0.014
Outstanding convertible preferred stock				191,406		191,406
Series C-2
Class Of Stock [Line Items]
Common stock, conversion basis						0.009
Outstanding convertible preferred stock				93,757		93,757
Series D And E Preferred Stock Cumulative Dividends
Class Of Stock [Line Items]
Outstanding convertible preferred stock				374,632		374,632			374,632
Preferred stock cumulative dividends | $								$ 7,643,378
Series E Warrants
Class Of Stock [Line Items]
Purchase of warrant exercise price per share | $ / shares			$ 0.001
Purchase price of preferred stock per Series E warrant | $ / shares		$ 0.0001	0.0001
Warrants exercise price | $ / shares		$ 0.001	$ 0.001
Financial institution warrant issued, share		118,017	11,366,486
Proceeds from Issuance of preferred stock and warrants | $		$ 77,634	$ 7,476,879
Fair value of warrants | $				$ 1,890,000		$ 1,890,000
Warrant Issuance Costs | $						$ 48,384
Preferred stock accreted redemption period						5 years
Series E Warrants | Maximum
Class Of Stock [Line Items]
Financial institution warrant issued, share			33,044,008
Series E Warrants | Series E Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Convertible preferred stock, price per share | $ / shares				$ 0.1645		$ 0.1645
Tranche One | Series E Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Financial institution warrant issued, share			49,566,012
Tranche One | Series E Warrants
Class Of Stock [Line Items]
Financial institution warrant issued, share			16,522,004

Redeemable Convertible Prefer48

Redeemable Convertible Preferred Stock - Schedule of Preferred Stock (Details) - USD ($)	May. 11, 2015	May. 31, 2015	Jun. 30, 2015
Class Of Stock [Line Items]
Conversion of preferred stock into common stock at initial public offering	$ 48,547,984		$ 57,356,049
Preferred Shares Before IPO	217,515,139
Common Shares After IPO	2,134,192		2,134,192
Carrying value including cumulative dividends	$ 57,356,049
Preferred shares before IPO including cumulative dividends		217,515,139
Common shares after IPO including dividends			2,508,824
Series A Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Conversion of preferred stock into common stock at initial public offering	$ 1,403,007		$ (1,403,007)
Preferred Shares Before IPO	1,292,084		(1,292,084)
Common Shares After IPO			38,973
Series B Preferred Stock
Class Of Stock [Line Items]
Conversion of preferred stock into common stock at initial public offering	$ 2,100,149		$ (2,100,149)
Preferred Shares Before IPO	6,789,712		(6,789,712)
Common Shares After IPO			75,835
Series C-1
Class Of Stock [Line Items]
Conversion of preferred stock into common stock at initial public offering	$ 4,569,063
Preferred Shares Before IPO	13,242,612
Common Shares After IPO			191,406
Series C-2
Class Of Stock [Line Items]
Conversion of preferred stock into common stock at initial public offering	$ 2,225,619
Preferred Shares Before IPO	9,948,331
Common Shares After IPO			93,757
Series D Preferred Stock
Class Of Stock [Line Items]
Conversion of preferred stock into common stock at initial public offering	$ 30,370,273		$ (38,163,280)
Preferred Shares Before IPO	140,252,678		(140,252,678)
Common Shares After IPO			1,305,984
Series E Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Conversion of preferred stock into common stock at initial public offering	$ 7,879,873		$ (8,894,931)
Preferred Shares Before IPO	45,989,722		(45,989,722)
Common Shares After IPO			428,237
Series D And E Preferred Stock Cumulative Dividends
Class Of Stock [Line Items]
Common Shares After IPO	374,632		374,632
Cumulative Dividends	$ 8,808,065

Stockholders Equity (Deficit) -

Stockholders Equity (Deficit) - Additional Information (Details) - USD ($)	1 Months Ended	6 Months Ended
	Feb. 28, 2014	Jun. 30, 2015	May. 11, 2015	Dec. 31, 2014	Feb. 04, 2014
Class Of Stock [Line Items]
Amendment date of entity incorporation		May 11, 2015
Common stock, shares authorized		200,000,000		600,000,000	600,000,000
Common stock, par value		$ 0.001		$ 0.001
Common stock, shares issued		6,827,414		334,003
Common stock, voting rights		Each share of common stock is entitled to one vote. All shares of common stock rank equally as to voting and all other matters that the holders are entitled to vote on.
Common stock, conversion features		The shares of common stock have no preemptive or conversion rights, no redemption or sinking fund provisions, no liability for further call or assessment, and are not entitled to cumulative voting rights
Preferred stock, shares authorized		10,000,000		0
Preferred stock, par value		$ 0.001		$ 0.001
Vesting period of options		2 years 8 months 12 days
Options to purchase common stock outstanding		610,090		595,577
Options fully vested		356,050
Unrecognized compensation expense		$ 674,100
Compensation expense related to unvested stock options, period expected to be recognized		3 years
2014 Equity Incentive Plan
Class Of Stock [Line Items]
Shares reserved for issuance			940,112
Number of shares available for issuance		923,031
Employee Stock Option | 2011 Equity Incentive Plan
Class Of Stock [Line Items]
Shares reserved for issuance			14,006
Employee Stock Option | 2011 Equity Incentive Plan
Class Of Stock [Line Items]
Percentage of increase on outstanding shares	20.00%

Stockholders Equity (Deficit)50

Stockholders Equity (Deficit) - Summary of Stock Option Plans Activity (Details) - USD ($)	1 Months Ended					6 Months Ended		12 Months Ended
	Jun. 30, 2015	May. 31, 2015	May. 31, 2014	Mar. 31, 2014	Jan. 31, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Shares, Beginning Balance						595,577
Number of Shares, Granted	12,083	5,000	8,685	249,361	2,094	17,083	260,140
Number of Shares, Exercised						(1,316)
Number of Shares, Forfeited						(1,254)
Number of Shares, Ending Balance	610,090					610,090		595,577
Number of Shares, Vested and expected to vest	597,358					597,358
Number of Shares, Exercisable	356,050					356,050
Weighted-Average Exercise Price Per Share, Beginning Balance						$ 3.71
Weighted-Average Exercise Price Per Share, Granted	$ 13.83	$ 14.64	$ 2.15	$ 2.15	$ 2.15
Weighted-Average Exercise Price Per Share, Exercised						4.24
Weighted-Average Exercise Price Per Share, Forfeited						8.41
Weighted-Average Exercise Price Per Share, Ending Balance	3.99					3.99		$ 3.71
Weighted-Average Exercise Price Per Share, Vested and expected to vest	3.91					3.91
Weighted-Average Exercise Price Per Share, Exercisable	$ 3.38					$ 3.38
Weighted-Average Remaining Contractual Life, Outstanding						7 years 4 months 24 days		7 years 9 months 18 days
Weighted-Average Remaining Contractual Life, Vested and expected to vest						7 years 3 months 18 days
Weighted-Average Remaining Contractual Life, Exercisable						6 years 4 months 24 days
Aggregate Intrinsic Value, Ending Balance	$ 5,449,483					$ 5,449,483
Aggregate Intrinsic Value, Vested and expected to vest	5,379,404					5,379,404
Aggregate Intrinsic Value, Exercisable	$ 3,386,727					$ 3,386,727

Stockholders Equity (Deficit)51

Stockholders Equity (Deficit) - Summary of Stock Option Grant Activity and Related Fair Value Information (Details) - $ / shares	1 Months Ended					6 Months Ended
	Jun. 30, 2015	May. 31, 2015	May. 31, 2014	Mar. 31, 2014	Jan. 31, 2014	Jun. 30, 2015	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options Granted	12,083	5,000	8,685	249,361	2,094	17,083	260,140
Exercise Price	$ 13.83	$ 14.64	$ 2.15	$ 2.15	$ 2.15
Fair Value of Common Stock on Date of Grant	$ 13.83	$ 14.64	$ 2.15	$ 2.15	$ 2.15

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)	1 Months Ended		6 Months Ended
	Oct. 31, 2012	Jun. 30, 2012	Jun. 30, 2015
Commitments And Contingencies [Line Items]
Percentage of requisite preferred holders who approved plan to set aside proceeds of any sale of to be distributed	60.00%
Lease expiration term			The Company leases office and laboratory space under two non-cancelable operating leases in Tucson, Arizona, which were set to expire in November and December 2015, respectively, as of June 30, 2015. Under the terms of the two Tucson leases, the Company had one option to extend the leases for five years at the end of the initial seven year lease term.
Lease extension term, in years			5 years
Expected increase in lease rent			$ 804,000
Additional commitment expense			$ 500,000
Merck Sharp And Dohme Corporation [Member]
Commitments And Contingencies [Line Items]
Non-exclusive license agreement, milestone accrued or paid		$ 0
Tucson
Commitments And Contingencies [Line Items]
Lease extension term, in years			5 years
Lease term			7 years
Minimum
Commitments And Contingencies [Line Items]
Percentage of proceeds of any sale to be distributed to employees, directors, or consultants	15.00%
Minimum | Merck Sharp And Dohme Corporation [Member]
Commitments And Contingencies [Line Items]
Non-exclusive license agreement, contingent milestone payments		$ 50,000
Non-exclusive license agreement, future royalties		3.00%
Maximum | Merck Sharp And Dohme Corporation [Member]
Commitments And Contingencies [Line Items]
Non-exclusive license agreement, contingent milestone payments		$ 1,000,000
Non-exclusive license agreement, future royalties		6.00%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income tax examination, likelihood of unfavorable settlement			Greater than 50 percent
Accrued interest or penalties	$ 0		$ 0		$ 0
Recognized interest or penalties	$ 0	$ 0	$ 0	$ 0

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2015USD ($)Agreement	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)Agreement	Jun. 30, 2014USD ($)
Related Party Transaction [Line Items]
Number of consulting agreement | Agreement	2		2
Series D Stock Holder
Related Party Transaction [Line Items]
Consulting fees paid to stockholder	$ 0	$ 11,250	$ 0	$ 22,250
Series E Stock Holder
Related Party Transaction [Line Items]
Consulting fees paid to stockholder	$ 0	$ 11,250	$ 0	$ 22,250

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($)	Aug. 04, 2015	Aug. 31, 2014
Growth Term Loan B
Subsequent Event [Line Items]
Term loan payable		$ 5,000,000
Subsequent Event
Subsequent Event [Line Items]
Lease term	5 years
Future minimum payment due for lease addition in period	$ 804,000
Payments for Tenant Improvements	$ 500,000
Subsequent Event | Growth Term Loan
Subsequent Event [Line Items]
Loan agreement amendment date	Aug. 31, 2015
Debt instrument extended interest only payment date	Apr. 1, 2016
Debt instrument fee payment description	It further changed the prepayment fee schedule such that the Company will be obligated to pay a prepayment fee equal to (i) 3% of the principal amount prepaid if the growth term loan is prepaid on or before the first anniversary of the amendment, (ii) 2% of the principal amount repaid if the growth term loan is prepaid after the first anniversary but on or prior to the second anniversary of the amendment and (iii) 1% of the principal amount repaid if the growth term loan is repaid after the second anniversary of the amendment and prior to maturity. The amendment increased the final payment percentage to 4.75%.
Percentage of prepayment fee on principal amount prepaid in next twelve months	3.00%
Percentage of prepayment fee on principal amount repaid in year two	2.00%
Percentage of prepayment fee on principal amount repaid in after two years	1.00%
Debt instrument final payment percentage	4.75%
Subsequent Event | Growth Term Loan B
Subsequent Event [Line Items]
Term loan payable	$ 5,000,000
Extended debt draw period maturity date	Mar. 31, 2016
Debt instrument, frequency of periodic payment	altered the repayment schedule to allow for repayment of borrowed principal over the course of 30 months beginning April 1, 2016
Debt instrument, date of first required payment	Apr. 1, 2016

Subsequent Events - Minimum Lea

Subsequent Events - Minimum Lease Payments Before Common Area Maintenance Charges (Details)	Jun. 30, 2015USD ($)
Subsequent Events [Abstract]
2,016	$ 507,948
2,017	510,323
2,018	512,734
2,019	515,181
2,020	$ 517,664